Misonix (MSON) 10-K 5 Sep 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2019	Sep. 03, 2019	Dec. 31, 2018
Document And Entity Information
Entity Registrant Name	MISONIX INC
Entity Central Index Key	0000880432
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-K
Document Period End Date	Jun. 30, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		9,649,103
Entity Public Float			$ 124,300,000
Entity File Number	1-10986
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 7,842,403	$ 10,979,455
Accounts receivable, less allowance for doubtful accounts of $100,000 and $200,000, respectively	5,360,454	5,245,549
Inventories, net	7,353,562	5,019,886
Prepaid expenses and other current assets	835,044	611,647
Total current assets	21,391,463	21,856,537
Property, plant and equipment, net of accumulated amortization and depreciation of $10,545,810 and $9,023,235, respectively	4,198,721	4,188,378
Patents, net of accumulated amortization of $1,204,589 and $1,063,393, respectively	779,100	757,447
Goodwill	1,701,094	1,701,094
Contract assets	960,000
Intangible and other assets	920,921	517,295
Total assets	29,951,299	29,020,751
Current liabilities:
Accounts payable	5,357,736	1,794,098
Accrued expenses and other current liabilities	2,488,514	2,812,172
Total current liabilities	7,846,250	4,606,270
Non current liabilities	401,000	13,303
Total liabilities	8,247,250	4,619,573
Commitments and contingencies
Shareholders' equity:
Common stock, $.01 par value-shares authorized 40,000,000; 9,646,728 and 9,430,466 shares issued and outstanding in each period	96,468	94,305
Additional paid-in capital	43,500,478	39,772,973
Accumulated deficit	(21,892,897)	(15,466,100)
Total shareholders' equity	21,704,049	24,401,178
Total liabilities and shareholders' equity	$ 29,951,299	$ 29,020,751

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 100,000	$ 200,000
Accumulated amortization and depreciation	10,545,810	9,023,235
Patents, Accumulated amortization	$ 1,204,589	$ 1,063,393
Common stock, par value (in dollars per share)	$ 0.01	$ .01
Common stock, authorized	40,000,000	40,000,000
Common stock, issued	9,646,728	9,430,466
Common stock, outstanding	9,646,728	9,430,466

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Revenues
Product	$ 38,848,491	$ 32,669,826
License		4,010,000
Total revenue	38,848,491	36,679,826
Cost of goods sold	11,568,339	9,794,898
Gross profit	27,280,152	26,884,928
Operating expenses:
Selling expenses	18,343,837	16,368,381
General and administrative expenses	11,878,209	9,063,139
Research and development expenses	4,467,969	4,394,149
Total operating expenses	34,690,015	29,825,669
Loss from operations	(7,409,863)	(2,940,741)
Other income (expense):
Interest income	89,856	26,123
Royalty income		525,438
Other	(38,243)	2,274
Total other income	51,613	553,835
Loss from continuing operations before income taxes	(7,358,250)	(2,386,906)
Income tax expense	28,547	5,416,646
Net loss from continuing operations	(7,386,797)	(7,803,552)
Discontinued operations:
Gain from sale of discontinued operations net of tax of $0 and $58,883, respectively		191,117
Net income from discontinued operations		191,117
Net loss	$ (7,386,797)	$ (7,612,435)
Continuing operations:
Basic	$ (0.79)	$ (0.87)
Diluted	(0.79)	(0.87)
Discontinued operations
Basic		0.02
Diluted		0.02
Combined
Basic	(0.79)	(0.85)
Diluted	$ (0.79)	$ (0.85)
Weighted average shares - Basic	9,333,117	9,009,189
Weighted average shares - Diluted	9,333,117	9,009,189

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Gain from sale of discontinued operations tax	$ 0	$ 58,883

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($)	Common Stock	Treasury Stock	Additional paid-in capital	Accumulated deficit	Total
Balance at beginning at Jun. 30, 2017	$ 93,572		$ 36,808,810	$ (8,762,540)	$ 28,139,842
Balance at beginning, shares at Jun. 30, 2017	9,357,166
Cumulative effect of the adoption of ASC 606 - revenue recognition				908,875	908,875
Net loss				(7,612,435)	(7,612,435)
Proceeds from exercise of stock options	$ 733		335,335		$ 336,068
Proceeds from exercise of stock options, shares	73,300				73,300
Stock-based compensation			2,628,828		$ 2,628,828
Balance at ending at Jun. 30, 2018	$ 94,305		39,772,973	(15,466,100)	24,401,178
Balance at ending, shares at Jun. 30, 2018	9,430,466
Cumulative effect of the adoption of ASC 606 - revenue recognition				960,000	960,000
Net loss				(7,386,797)	(7,386,797)
Proceeds from exercise of stock options	$ 2,163		1,391,366		$ 1,393,529
Proceeds from exercise of stock options, shares	216,262				216,262
Stock-based compensation			2,336,139		$ 2,336,139
Balance at ending at Jun. 30, 2019	$ 96,468		$ 43,500,478	$ (21,892,897)	$ 21,704,049
Balance at ending, shares at Jun. 30, 2019	9,646,728

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities
Net loss	$ (7,386,797)	$ (7,612,435)
Net income from discontinued operations		(191,117)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization	1,663,771	1,427,225
Bad debt expense	61,676	55,390
Deferred income tax expense		5,243,422
Stock-based compensation	2,336,139	2,628,828
Deferred lease liability and income	(13,303)	(9,138)
Changes in operating assets and liabilities:
Accounts receivable	(176,581)	(167,550)
Inventories	(3,182,768)	(1,410,356)
Prepaid expenses and other current assets	(223,397)	72,833
Other assets	135,374
Accounts payable, accrued expenses and other current liabilities	3,101,980	(601,096)
Net cash used in operating activities	(3,683,906)	(563,994)
Investing activities
Acquisition of property, plant and equipment	(683,826)	(375,419)
Additional patents	(162,849)	(165,388)
Net cash used in investing continuing activities	(846,675)	(540,807)
Net cash provided by investing activities - discontinued operations		191,117
Net cash used in investing activities	(846,675)	(349,690)
Financing activities
Proceeds from sale of common stock
Proceeds from exercise of stock options	1,393,529	336,068
Net cash provided by financing activities	1,393,529	336,068
Net decrease in cash and cash equivalents	(3,137,052)	(577,616)
Cash and cash equivalents at beginning of year	10,979,455	11,557,071
Cash and cash equivalents at end of year	7,842,403	10,979,455
Cash paid for:
Interest
Income taxes	77,576	704
Transfer of inventory to property, plant and equipment for consignment of product	849,092	1,382,904
Adoption of new accounting standard on deferred taxes		908,875
Accrued but unpaid costs to register equity for acquisition	$ 539,000

Basis of Presentation, Organiza

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies	1. Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies Basis of Presentation These consolidated financial statements of Misonix, Inc. ("Misonix" or the "Company") include the accounts of Misonix and its 100% owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Organization and Business Misonix designs, manufactures, develops and markets therapeutic ultrasonic devices. These products are used for precise bone sculpting, removal of soft tumors, and tissue debridement in the fields of orthopedic surgery, plastic surgery, neurosurgery, podiatry and vascular surgery. In the United States, our products are marketed primarily through a hybrid sales approach. This includes direct sales representatives, managed by regional sales managers, along with independent distributors. Outside the United States, we sell BoneScalpel and SonaStar to specialty distributors who purchase products from us to resell to their clinical customer bases. We sell to all major markets in the Americas, Europe, Middle East, Asia Pacific and Africa. The Company operates as one business segment. Pending Merger with Solsys Medical, LLC On May 2, 2019, the Company announced that it has entered into a definitive agreement with Solsys Medical, LLC ("Solsys"), a privately held regenerative medical company, to acquire Solsys in an all-stock transaction valued at approximately $97 million. The planned acquisition of Solsys is expected to substantially broaden Misonix's addressable market through wound care solutions that are complementary to its existing products. The transaction has been approved by both the Company's Board of Directors and the Solsys Board of Managers. After the completion of the transaction, it is expected that Misonix shareholders immediately prior to the closing will own 64% of the combined entity, and Solsys unitholders will own 36%. The completion of the acquisition and the issuance of shares in connection with the proposed transaction is subject to the approval by Misonix shareholders and the completion of the transaction is subject to approval by 55% of Solsys' Series E unitholders and a majority of its Common unitholders, Series A unitholders, Series B unitholders, Series C unitholders and Series D unitholders, voting as a single class, as well as the satisfaction of certain customary closing conditions. The Company will convene a special shareholder meeting to vote on the transaction. The Company anticipates that the transaction will close in the third quarter of calendar year 2019. Professional fees incurred during the year ended June 30, 2019 with respect to this matter were approximately $1.9 million. Approximately $539,000 of these costs relate to the registration of the common stock that will be issued to pay for the transaction. These costs are included in Intangible and other assets as of June 30, 2019 and will be applied against Additional paid-in capital upon closing of the transaction. High Intensity Focused Ultrasound Technology The Company sold its rights to the high intensity focused ultrasound technology to SonaCare Medical, LLC ("SonaCare") in May 2010. The Company may receive up to approximately $5.8 million in payment for the sale. SonaCare is required to pay the Company 7% of the gross revenues received from its sales of the (i) prostate product in Europe and (ii) kidney and liver products worldwide, until the Company has received payments of $3 million, and thereafter 5% of the gross revenues, up to an aggregate payment of $5.8 million, all subject to a minimum annual royalty of $250,000. Cumulative payments through June 30, 2019 were $2,542,579. SonaCare has defaulted on its royalty payment due on March 31, 2019, and the Company is in discussions with SonaCare regarding this default. Given that the payment is uncertain, the Company has not recorded any income relating to this payment. Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. All of the Company's cash is maintained in bank accounts and accordingly it does not have cash equivalents at June 30, 2019. The Company's cash balance at June 30, 2019 was $7,842,403. The Company maintains cash balances at various financial institutions. At June 30, 2019, these financial institutions held cash that was approximately $4,366,000 in excess of amounts insured by the Federal Deposit Insurance Corporation and other government agencies. Major Customers and Concentration of Credit Risk Included in sales from continuing operations are sales to the Company distributor of SonaStar in China of $151,949 and $6,969,258 for the fiscal years ended June 30, 2019 and 2018, respectively, inclusive of product licensing fees of $4,010,000. Accounts receivable from this customer were $14,850 at June 30, 2019. Also included in sales from continuing operations are sales to the Company's distributor of its BoneScalpel product in China of $4,473,534 and $0 for the fiscal years ended June 30, 2019 and 2018, respectively. Accounts receivable from this customer were $493,784 at June 30, 2019. Total royalties from Medtronic Minimally Invasive Therapies ("MMIT") related to its sales of the Company's ultrasonic cutting and sculpting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $0 and $525,000 for the fiscal years ended June 30, 2019 and 2018, respectively. There were no accounts receivable from MMIT royalties at June 30, 2019 and 2018, respectively. The license agreement with MMIT expired in August 2017. At June 30, 2019 and 2018, the Company's accounts receivable with customers outside the United States were approximately $2,181,000 and $1,630,000, respectively, none of which is over 90 days. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for but not limited to establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and related valuation allowances, and stock-based compensation. Actual results could differ from those estimates. Accounts Receivable Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist of raw materials, work-in process and finished goods and include purchased materials, direct labor and manufacturing overhead. Management evaluates the need to record adjustments to write down inventory to the lower of cost or net realizable value on a quarterly basis. The Company's policy is to assess the valuation of all inventories, including raw materials, work-in-process and finished goods and it writes down its inventory for estimated obsolescence based upon the age of inventory and assumptions about future demand and usage. Inventory items used for demonstration purposes, rentals or on consignment are classified as property, plant and equipment. Property, Plant and Equipment Property, plant and equipment are recorded at cost. Minor replacements and maintenance and repair expenses are charged to expense as incurred. Depreciation of property and equipment is provided using the straight-line method over estimated useful lives ranging from 3 to 5 years. Leasehold improvements are amortized over the life of the lease or the useful life of the related asset, whichever is shorter. The Company's policy is to periodically evaluate the appropriateness of the lives assigned to property, plant and equipment and make adjustments if necessary. Depreciation of BoneScalpel and SonicOne generators which are consigned to customers are depreciated over a 5- year period, and depreciation is charged to selling expenses. See Note 4. Revenue Recognition On July 1, 2018 the Company adopted Accounting Standards Codification ("ASC") Topic 606 "Revenue from Contracts with Customers, as amended" ("ASC Topic 606"), using the modified retrospective method applied to those contracts which were not completed as of the adoption date. The reported results for year ended June 30, 2019 reflect the application of Topic 606 guidance while the reported results for fiscal year 2018 were prepared under the guidance of ASC Topic 605, "Revenue Recognition". The adoption of ASC Topic 606 resulted in a cumulative prior period adjustment in the amount of $960,000 related to the Company's License and Exclusive Manufacturing Agreement described below, but the remainder of the adoption did not have a material impact on the timing or amount of revenue recognized. The impacts of adopting ASC Topic 606 on the Company's consolidated balance sheets as of July 1, 2018 were as follows: As Adjusted As ASC 606 Under Reported Adjustments ASC 606 Long-term contract assets $ - $ 960,000 $ 960,000 Total Shareholders' equity $ 24,401,178 $ 960,000 $ 25,361,178 The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC Topic 606: 1) the Company accounts for amounts collected from customers for sales and other taxes net of related amounts remitted to tax authorities; 2) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 3) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling, general and administrative expenses; 4) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer; 5) the Company will utilize the right-to-invoice practical expedient with regard to the recognition of revenue upon the purchase of consumable goods in connection with a product placement/consignment arrangement. The Company determines revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, a performance obligation is satisfied Contracts and Performance Obligations The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and related services identified in the contracts, purchase orders or invoices. For each contract, the Company considers the obligation to transfer products or bundled products and services to the customer, of which each is distinct in the context of the contract, to be performance obligations. The Company historically has not made provisions for returns and allowances as they have not been material to the operations of the Company. Transaction Price and Allocation to Performance Obligations Transaction prices of products are typically based upon contracted rates as specified on the purchase order for the purchase of consumables. The Company's contracted rates represent the standalone selling price of a consumable which is generally determined through the sale of products and/or bundled products or services separately in similar circumstances to similar customers. The Company determines the effects of variable consideration, inclusive of any constraints, in determining the transaction price with regard to its contracts with customers. Recognition of Revenue The Company satisfies performance obligations either over time, or at a point in time, upon which control transfers to the customer. Revenue derived from the shipping and billing of product is recorded upon shipment, when transfer of control occurs for products shipped freight on board ("F.O.B.") shipping point. Products shipped F.O.B. destination point are recorded as revenue when received at the point of destination when the transfer of control is completed. Shipments under agreements with distributors are not subject to return, and payment for these shipments is not contingent on sales by the distributor. Accordingly, the Company recognizes revenue on shipments to distributors in the same manner as with other customers under the ship and bill process. Revenue derived from the rental of equipment is recorded on a monthly basis over the term of the lease. Shipments of consumable products to these rental customers is recorded as orders are received and shipments are made F.O.B. destination or F.O.B. shipping point. Revenue derived from consignment agreements is earned as consumables product orders are fulfilled using the right to invoice practical expedient. Therefore, revenue is recognized as control passes to the customer, which is typically when shipments are made F.O B shipping point or F.O.B destination. Revenue derived from service and maintenance contracts is recognized evenly over the life of the service agreement as the services are performed. Contract Specific Performance Obligations and Significant Judgements Product Placement/Consignment Agreements The Company's product placement/consignment agreements provide for the placement of a generator at the customer's place of business and set pricing related to the purchase of consumables for use in conjunction with the generator. These agreements do not require any minimum consumable purchase quantities and do not have a stated term. The Company considers the transaction price in these arrangements to be fully constrained variable consideration because it is dependent on future sales of consumables to the customer. The Company has determined that the pattern of purchase of consumables by a customer is consistent with the benefit received by the customer for the use of the generator and therefore the Company has a right to consideration based upon the pattern of consumable purchases placed through purchase orders by the customer. The Company's invoices to these customers have short-term payment terms and are aligned with the transfer of goods and services to the customer and the Company recognizes revenue based upon its right to invoice customers. License and Manufacturing Agreement On October 19, 2017, the Company entered into a License and Exclusive Manufacturing Agreement (the "L&M Agreement") with Hunan Xing Hang Rui Kang Bio-technologies Co., Ltd, a Chinese corporation (the "Licensee") under which Misonix has licensed certain manufacturing and distribution rights to its SonaStar product line in China, Hong Kong and Macau. The Licensee was obligated to make an initial payment of $5,000,000 for the transfer of functional intellectual property and initial stocking orders of product. In addition, the Licensee is required to make minimum royalty payments of $2,000,000 per calendar year for three years beginning in 2019, based upon the manufacture of products by the Licensee. The Company collected $5,000,000 of initial revenue for the quarter ended March 31, 2018 under ASC 605. Upon the adoption of ASC Topic 606, the Company evaluated this contract under the provisions of the new revenue standard. The Company determined that the satisfied performance obligations and allocation of the transaction price related to the $5,000,000 received prior to adoption was consistent with the provisions of ASC Topic 606 and also recorded a transitional adjustment to accumulated deficit in the amount of $960,000 as follows: Minimum royalty revenue provided by the contract $ 6,000,000 Implicit price concession (5,040,000 ) Adoption adjustment to accumulated deficit under ASC 606 $ 960,000 Although the contract includes minimum royalties, the Company concluded that a significant portion of those guaranteed minimums are actually variable consideration subject to the constraint because the Company has provided an implicit price concession. Specifically, the fact that production of the product in China is not assured and the Licensee must develop a manufacturing process, coupled with the fact that new technology related to the product is expected to be available for sale domestically, may result in the Licensee not earning sufficient revenue in order to pay the minimum royalties. Therefore, the Company has determined variable consideration through utilization of the most likely method based upon forecasts and projections of shipment of products. The Company will monitor facts and circumstances over time and adjust management's most likely estimate of variable consideration on a quarterly basis. As of June 30, 2019, the Company updated its estimate and concluded the amount is not materially different. The uncertainties that existed at inception of the contract still exist at June 30, 2019. Disaggregation of Revenue The Company generates revenue from the sale and leasing of medical equipment and from the sale of consumable products used with medical equipment in surgical procedures as well as through product licensing arrangements. In the United States, the Company's products are marketed primarily through a hybrid sales approach which includes direct sales representatives, managed by regional sales managers, along with independent distributors. Outside the United States, the Company sells BoneScalpel and SonaStar to specialty distributors who purchase products to resell to their clinical customer bases. The Company sells to all major markets in the Americas, Europe, Middle East, Asia Pacific, and Africa. Revenue is disaggregated from contracts between products under ship and bill arrangements and licensing agreements, and by geography, which the Company believes best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. The Company also provides an immaterial amount of service revenue which is recognized over time, but not stated separately because the amounts are immaterial. The following table disaggregates the Company's product revenue by classification and geographic location: For the year ended 2019 2018 Total Consumables $ 28,371,517 $ 23,596,476 Equipment 10,476,974 9,073,350 Total Product 38,848,491 32,669,826 License Fee - 4,010,000 Total $ 38,848,491 $ 36,679,826 Domestic: Consumables $ 20,561,273 $ 17,735,749 Equipment 2,414,435 2,308,614 Total $ 22,975,708 $ 20,044,363 International: Consumables $ 7,810,244 $ 5,860,727 Equipment 8,062,539 6,764,736 Total $ 15,872,783 $ 12,625,463 Contract Assets The timing of revenue recognition, customer invoicing, and collections produces accounts receivable and contract assets on the Company's consolidated balance sheet. Contract liabilities are not material to the operations of the Company as of June 30, 2019. The Company invoices in accordance with contract payment terms. Invoices to customers represent an unconditional right of the Company to receive consideration. When revenue is recognized in advance of customer invoicing a contract asset is recorded. Unpaid customer invoices are reflected as accounts receivable. The Company has established a contract asset in conjunction with the Company's L&M Agreement based upon its assessment of the most likely variable consideration to be received by the Company as a result of the royalty provisions in the contract. The asset is recorded as a long-term asset as the Company believes that payment will be made on this asset in a duration exceeding one year. Contract assets as of June 30, 2019 and June 30, 2018 were $960,000 and $0, respectively. Selling Costs Incremental direct costs of obtaining a sales contract primarily include sales commissions paid to sales personnel and outside sales representatives in connection with sales of products under ship and bill scenarios or through product placement scenarios. The expected period of benefit of these costs is one year or less and therefore the Company has elected the practical expedient to expense such costs in the period in which they are incurred. Typically, costs in fulfilling a contract represent shipping and handling costs and the Company accounts for these costs as fulfillment costs and they are expensed as incurred. Costs in fulfilling a contract are only capitalized as an asset if they relate directly to an existing contract or specific anticipated contract, they generate or enhance resources of the entity that will be used to satisfy performance obligations in the future, and they are expected to be recovered. The Company has not identified any such costs. Long-Lived Assets The carrying values of intangible and other long-lived assets, excluding goodwill, are periodically reviewed to determine if any impairment indicators are present. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization and depreciation period, their carrying values are reduced to estimated fair value. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated decline in revenue or operating profit, adverse legal or regulatory developments, accumulation of costs significantly in excess of amounts originally expected to acquire the asset and a material decrease in the fair value of some or all of the assets. Assets are grouped at the lowest levels for which there are identifiable cash flows that are largely independent of the cash flows generated by other asset groups. No such impairment was deemed to exist in fiscal 2019 and 2018. Goodwill Goodwill is not amortized. The Company reviews goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of this impairment test requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company's business, the useful lives over which cash flows will occur and determination of the Company's weighted average cost of capital. The Company also compares its market capitalization to the value of its goodwill to view for evidence of impairment. The Company completed its annual goodwill impairment tests for fiscal 2019 and 2018 as of March 31 of each year. No impairment of goodwill was deemed to exist in fiscal 2019 and 2018. Patents The cost of acquiring or processing patents is capitalized at cost. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Patents totaled $779,100 and $757,447 at June 30, 2019 and 2018, respectively. Amortization expense for the years ended June 30, 2019 and 2018 was approximately $141,200 and $127,000, respectively. The following is a schedule of estimated future patent amortization expense as of June 30, 2019 during the following fiscal years: 2020 $ 120,186 2021 112,993 2022 75,332 2023 74,241 2024 66,486 Thereafter 329,862 $ 779,100 Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible. Should management determine that it is more likely than not that some portion of the deferred tax asset will not be realized, a valuation allowance against the deferred tax asset would be established in the period such determination was made. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company classifies income tax related interest and penalties as a component of income tax expense. Earnings Per Share Earnings per share ("EPS") is calculated using the two class method, which allocates earnings among common stock and participating securities to calculate EPS when an entity's capital structure includes either two or more classes of common stock or common stock and participating securities. Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities. As such, unvested shares of restricted stock of the Company are considered participating securities. The dilutive effect of options and their equivalents (including non-vested stock issued under stock based compensation plans), is computed using the "treasury" method. Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding: For the years ended 2019 2018 Basic weighted average shares outstanding 9,333,117 9,009,189 Dilutive effect of restricted stock awards (participating securities) - - Denominator for basic earnings per share 9,333,117 9,009,189 Dilutive effect of stock options - - Diluted weighted average shares outstanding 9,333,117 9,009,189 Diluted EPS for the years ended June 30, 2019 and 2018 as presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. Accordingly, excluded from the calculation of diluted EPS are the dilutive effect of options to purchase 482,926 and 211,801 shares of common stock for the years ended June 30, 2019 and 2018, respectively. Also excluded from the calculation of both basic and diluted earnings per share for the years ended June 30, 2019 and 2018 are the 400,000 shares of restricted common stock which were issued in December 2016. Research and Development All research and development expenses are expensed as incurred and are included in operating expenses. Advertising Expense The cost of advertising is expensed in the period the advertising first takes place. The Company incurred approximately $47,000, and $0 in advertising costs during the fiscal years ended June 30, 2019 and 2018, respectively. Advertising costs are reported in selling expenses on the statement of operations. Depreciation Expense for Consigned Inventory The Company typically provides to its United States customers, on a consignment basis, the generators used to power its BoneScalpel and SonicOne products. Title to these generators remains at all times with the Company. When these generators are deployed in the field at customer locations, the Company depreciates these units over a five-year period and charges the depreciation to selling expenses. Depreciation expense relating to consigned generators and for demonstration equipment for the years ended June 30, 2019 and 2018 was $1,093,000 and $923,000, respectively. Shipping and Handling Shipping and handling fees for the fiscal years ended June 30, 2019 and 2018 were approximately $83,000 and $99,000, respectively, and are reported as a component of net sales. Shipping and handling costs for the fiscal years ended June 30, 2019 and 2018 were approximately $563,000 and $289,000, respectively, and are reported as a component of selling expenses. Stock-Based Compensation The Company measures compensation cost for all share based payments at fair value and recognizes the cost over the vesting period. The Company uses the Black-Scholes method to value awards and utilizes the straight line amortization method to recognize the expense associated with the awards with graded vesting terms. Restricted Stock Awards The Company measures compensation cost for all restricted stock awards at fair value and recognizes the cost over the vesting period. For awards that have market conditions, the Company uses the Monte Carlo valuation method to value awards and utilizes the straight line amortization method to recognize the expense associated with the awards with graded vesting terms. Where awards have performance conditions, the Company will determine the probability of achieving those conditions and will record compensation expense when it is probable that the conditions will be met. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instrument. ASU 2016-13 replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for SEC filers for interim and annual periods beginning after December 15, 2019. Management is currently assessing the impact ASU 2016-13 will have on the Company, but it is not expected to have a material impact on the Company's financial statements. There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows. Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), and has since issued amendments thereto, related to the accounting for leases (collectively referred to as "ASC 842"). ASC 842 establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The Company will adopt ASC 842 on July 1, 2019. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Entities have the option to continu

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	2. Fair Value of Financial Instruments The Company follows a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of "observable inputs" and minimize the use of "unobservable inputs." The three levels of inputs used to measure fair value are as follows: Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date. Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability. At June 30, 2019 and 2018, all of the Company's cash and cash equivalents, trade accounts receivable and trade accounts payable were short term in nature, and their carrying amounts approximate fair value.

Inventories

Inventories	12 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	3. Inventories Inventories are summarized as follows: June 30, June 30, Raw material $ 4,830,207 $ 3,540,205 Work-in-process 224,252 180,442 Finished goods 2,743,361 1,743,497 7,797,820 5,464,144 Less valuation reserve (444,258 ) (444,258 ) $ 7,353,562 $ 5,019,886

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	4. Property, Plant and Equipment Property, plant and equipment consist of the following: June 30, June 30, Demonstration and consignment inventory $ 9,076,970 $ 8,227,878 Machinery and equipment 2,793,908 2,582,244 Furniture and fixtures 1,471,371 1,464,325 Leasehold improvements 691,751 691,751 Software systems 688,203 223,087 Automobiles 22,328 22,328 14,744,531 13,211,613 Less: accumulated depreciation and amortization (10,545,810 ) (9,023,235 ) $ 4,198,721 $ 4,188,378 Depreciation and amortization of property, plant and equipment totaled approximately $1,500,000 and $1,300,000 for the fiscal years ended June 30, 2019 and 2018, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5 Accrued Expenses and Other Current Liabilities The following summarizes accrued expenses and other current liabilities: June 30, June 30, 2019 2018 Accrued payroll, payroll taxes and vacation $ 488,339 $ 351,435 Accrued bonus 622,115 552,988 Accrued commissions 662,007 742,807 Professional fees 181,313 102,065 Deferred foreign vendor taxes (1) - 401,000 Vendor, tax and other accruals 534,740 661,877 $ 2,488,514 $ 2,812,172 (1) Reclassified to non-current liabilities in fiscal 2019

Stock-Based Compensation Plans

Stock-Based Compensation Plans	12 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Stock-Based Compensation Plans	6. Stock-Based Compensation Plans At June 30, 2019, the Company had outstanding equity-linked grants under nine stock-based compensation plans (the “Plans”), as follows: Plan Initial Granted Exercised Expired / Forfeited Outstanding Available 2001 Employee Stock Option Plan 1,000,000 1,251,261 376,368 869,455 5,438 - 2005 Employee Equity Incentive Plan 500,000 547,125 494,200 48,925 4,000 - 2005 Non Employee Director Stock Option Plan 500,000 195,000 127,500 52,500 15,000 - 2009 Employee Equity Incentive Plan 500,000 624,925 399,407 129,350 96,168 - 2009 Non Employee Director Stock Option Plan 200,000 230,000 60,000 56,250 113,750 4,425 2012 Employee Equity Incentive Plan 500,000 732,000 190,999 242,501 298,500 10,501 2012 Non Employee Director Stock Option Plan 200,000 237,500 37,500 56,250 143,750 18,750 2014 Employee Equity Incentive Plan 750,000 945,000 81,874 223,876 639,250 28,876 2017 Equity Incentive Plan 750,000 285,000 - 37,000 248,000 499,000 Total 1,563,856 561,552 The compensation cost that has been charged against income for these plans, excluding the compensation cost for restricted stock, was $1,221,233 and $1,728,491 for the fiscal years ended June 30, 2019 and 2018, respectively, and is recorded in the department associated with the employee to which the grants are issued. The expense for fiscal 2018 included a reversal of stock compensation from prior periods due to forfeitures of unvested options of $625,202. As of June 30, 2019, there was $3,770,549 of total unrecognized compensation cost to be recognized over a weighted-average period of 2.6 years, which includes $1,133,743 of unrecognized compensation expense on restricted stock awards. Stock options typically expire 10 years from the date of grant and vest over service periods, which typically are 4 years. All options are granted at the price of the Common Stock on the NASDAQ Stock Market on the date of grant as set forth in the Plans. The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. The expected volatility represents the historical price changes of the Company’s stock over a period equal to that of the expected term of the option. The Company uses the simplified method for determining the option term. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The expected dividend yield is based upon historical and projected dividends. The Company has historically not paid dividends, and is not expected to do so in the near term. The weighted average fair value at date of grant for options granted during the fiscal years ended June 30, 2019 and 2018 was $16.64 and $5.50 per share, respectively. The fair value was estimated based on the weighted average assumptions of: For the years ended 2019 2018 Risk-free interest rates 2.80 % 1.98 % Expected option life in years 6.25 5.95 Expected stock price volatility 56.01 % 57.42 % Expected dividend yield 0 % 0 % A summary of option activity under the Plans as of June 30, 2019 and 2018, and changes during the years ended on those dates is presented below: Options Outstanding Weighted Average Exercise Aggregate Vested and exercisable at June 30, 2017 517,361 $ 6.33 $ 1,923,794 Granted 305,500 10.10 Exercised (76,418 ) 5.47 Forfeited (15,125 ) 7.89 Expired (75,000 ) 4.87 Outstanding as of June 30, 2018 1,330,193 $ 8.47 $ 5,369,557 Vested and exercisable at June 30, 2018 681,316 $ 7.67 $ 3,355,240 Granted 255,000 16.64 Exercised (245,835 ) 7.96 Forfeited (160,502 ) 10.15 Expired (15,000 ) 2.66 Outstanding as of June 30, 2019 1,163,856 $ 10.28 $ 17,617,231 Vested and exercisable at June 30, 2019 656,730 $ 8.42 $ 11,162,650 The total fair value of shares vested during the year ended June 30, 2019 was $2,351,268. The number and weighted-average grant-date fair value of non-vested stock options at the beginning of fiscal 2019 was 648,877 and $5.08, respectively. The number and weighted-average grant-date fair value of stock options which vested during fiscal 2019 was 240,624 and $5.14, respectively. The following table summarizes information about stock options outstanding and exercisable at June 30, 2019: Options Outstanding Options Exercisable Weighted Average Weighted Weighted Range of Contractual Average Average Exercise Prices Life Exercise Exercise Low High Number (Yrs.) Price Number Price $ 1.82 - $ 6.98 225,106 4.6 $ 4.89 183,606 $ 4.47 $ 6.99 - $ 9.45 237,125 5.9 $ 8.21 197,249 $ 8.14 $ 9.46 - $ 10.23 246,125 7.9 $ 9.84 124,625 $ 9.74 $ 10.24 - $ 13.35 223,500 6.9 $ 11.75 149,250 $ 12.49 $ 13.36 - $ 19.84 232,000 9.3 $ 16.70 2,000 $ 13.89 1,163,856 6.9 $ 10.28 656,730 $ 8.42 Stock options are granted with exercise prices not less than the fair market value of the Company’s Common Stock, at the time of the grant, with an exercise term as determined by the Committee administering the applicable option plan (the “Committee”) not to exceed 10 years. The Committee determines the vesting period for the Company’s stock options. Generally, such stock options have vesting periods of immediate to four years. Certain option awards provide for accelerated vesting upon meeting specific retirement, death or disability criteria, and upon change of control. During the fiscal years ended June 30, 2019 and 2018, the Company granted options to purchase 255,000 and 305,500 shares of Common Stock, respectively. Stock options are granted with exercise prices not less than the fair market value of the Company’s Common Stock, at the time of the grant, with an exercise term as determined by the compensation committee of the Company’s board of directors (the “Committee”) not to exceed 10 years. The Committee determines the vesting period for the Company’s stock options. Generally, such stock options have vesting periods of immediate to four years. Certain option awards provide for accelerated vesting upon meeting specific retirement, death or disability criteria, and upon change of control. Restricted Stock Awards On December 15, 2016, the Company issued 400,000 shares of restricted stock to its Chief Executive Officer. These awards vest over a period of up to five years, subject to meeting certain service, performance and market conditions. These awards were valued at approximately $3.6 million and compensation expense recorded for the years ended June 30, 2019 and 2018 was $1,114,906 and $900,337, respectively. At June 30, 2019, there was $1,133,743 of unrecognized compensation cost to restricted stock awards to be recognized over a weighted-average period of 2.3 years. The awards contain a combination of vesting terms which include time vesting, performance vesting relating to revenue achievement, and market vesting related to obtaining certain levels of Company stock prices. During fiscal 2019, the performance conditions of one of these restricted stock awards were met, resulting in the full amortization of this award during the period, totaling $475,286 of additional amortization during the period. The number of restricted stock awards which vested was 133,333. At June 30, 2019, the Company has estimated that it is probable that the performance conditions will be met. The awards were valued using a Monte Carlo valuation model using a stock price at the date of grant of $9.60, a term of 3 to 5 years, a risk free interest rate of 1.6% to 2.1% and a volatility factor of 66.5%.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Leases The Company has entered into several non-cancellable operating leases for the rental of certain manufacturing and office space, equipment and automobiles expiring in various years through 2021. The principal building lease provides for a monthly rental of approximately $29,000. The following is a schedule of future minimum lease payments, by year and in the aggregate, under operating leases with initial or remaining terms of one year or more at June 30, 2019: Operating Leases 2020 $ 365,942 2021 96,517 Total mimimun lease payments $ 462,459 Certain of the leases provide for escalation clauses, renewal options and the payment of real estate taxes and other occupancy costs. Rent expense for all operating leases was approximately $422,000 and $435,000 for the fiscal years ended June 30, 2019 and 2018, respectively. Purchase Commitments As of June 30, 2019 and 2018, the Company had purchase and inventory commitments totaling $5,518,842 and $3,841,641, respectively. Class Action Securities Litigation On September 19, 2016, Richard Scalfani, an individual shareholder of Misonix, filed a lawsuit against the Company and its former chief executive officer and chief financial officer in the U.S. District Court for the Eastern District of New York, alleging violations of the federal securities laws. The complaint alleges that the Company's stock price was artificially inflated between November 5, 2015 and September 14, 2016 as a result of alleged false and misleading statements in the Company's securities filings concerning the Company's business, operations, and prospects and the Company's internal control over financial reporting. Scalfani filed the action seeking to represent a putative class of all persons (other than defendants, officers and directors of the Company, and their affiliates) who purchased publicly traded Misonix securities between November 5, 2015 and September 14, 2016. Scalfani was seeking an unspecified amount of damages for himself and for the putative class under the federal securities laws. On March 24, 2017, the Court appointed Scalfani and another individual Misonix shareholder, Tracey Angiuoli, as lead plaintiffs for purposes of pursuing the action on behalf of the putative class. The lead plaintiffs, on behalf of the putative class, and the Company reached a settlement in principle under which the Company would pay $500,000 to resolve the matter. The district court approved the settlement and dismissed the lawsuit with prejudice in an order dated December 16, 2017. The Company has paid its $250,000, representing its insurance retention. The balance was paid by the Company's insurance carrier. Former Chinese Distributor – FCPA With the assistance of outside counsel, the Company conducted a voluntary investigation into the business practices of the independent Chinese entity that previously distributed the Company's products in China and the Company's knowledge of those business practices, which may have had implications under the FCPA, as well as into various internal control[s] issues identified during the investigation (the "Investigation"). The Company has not identified any information through the Investigation or otherwise that suggests that the Company's previously reported financial statements are incorrect. On September 27, 2016 and September 28, 2016, the Company voluntarily contacted the SEC and the DOJ, respectively, to advise both agencies of these potential issues. Thereafter, the Company provided documents and information to, and cooperated fully with, the SEC and the DOJ, in their investigations of these matters. On June 18, 2019, the Division of Enforcement of the SEC advised the Company by letter that the SEC had concluded its investigation of Misonix, Inc. and that, based on the information it had as of the date of the letter, it did not intend to recommend an enforcement action by the SEC against the Company. On August 13, 2019, the Company received a declination letter from the DOJ stating that the DOJ had closed its inquiry into Misonix without any action against the Company. The investigative costs to date, including costs of litigation relating to the Company's former Chinese distributor as described below, are approximately $3.9 million to date, of which $0.8 million, $0.5 million and $2.4 million was charged to expense during the three years ended June 30, 2019, respectively. Former Chinese Distributor - Litigation On March 23, 2017, the Company's former distributor in China, Cicel (Beijing) Science & Technology Co., Ltd., filed a lawsuit against the Company and certain officers and directors of the Company in the United States District Court for the Eastern District of New York, alleging that the Company improperly terminated its contract with the former distributor. The complaint sought various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, and asserted various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. On October 7, 2017, the court granted the Company's motion to dismiss all of the tort claims asserted against it, and also granted the individual defendants' motion to dismiss all claims asserted against them. The only claim currently remaining in the case is for breach of contract against the Company; the plaintiff has moved to amend its complaint to add tort claims, which the Company has opposed. The court has not yet ruled on the motion to amend. The Company believes it has various legal and factual defenses to the allegations in the complaint, and intends to vigorously defend the action. Fact discovery in the case is ongoing, and there is no trial date currently set. Stockholder Derivative Litigation On June 6, 2017, Irving Feldbaum, an individual shareholder of Misonix, filed a lawsuit in the U.S. District Court for the Eastern District of New York. The complaint alleges claims against the Company's board of directors, its former chief executive officer and chief financial officer, certain of its former directors, and the Company as a nominal defendant for alleged violations of Section 14(a) of the Securities Exchange Act of 1934 and state law claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment. The complaint alleges that the Company incurred damages as a result of alleged false and misleading statements in the Company's securities filings concerning the Company's business, operations, prospects and the Company's internal control over financial reporting. The complaint also alleges that the Company's February 4, 2016 Proxy Statement contained false and misleading statements regarding executive compensation. The complaint seeks the recovery of damages on behalf of the Company and the implementation of changes to corporate governance procedures. On June 16, 2017, Michael Rubin, another individual shareholder of Misonix, filed a case alleging similar claims in the same district court. On July 21, 2017, the district court consolidated the two actions for all purposes. On July 26, 2019, the district court approved the settlement. Under the terms of the settlement, the Company has agreed to undertake and maintain in place certain corporate governance reforms for a period of time, and to pay counsel for Mr. Feldbaum and Mr. Rubin attorneys' fee of $500,000, which has been paid by Misonix's insurance carrier.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions Minoan Medical (Pty) Ptd. (“Minoan”) (formerly Applied BioSurgical) is an independent distributor for the Company in South Africa. The chief executive officer of Minoan is also the brother of Stavros G. Vizirgianakis, the CEO of Misonix, Inc. Set forth below is a table showing the Company’s net revenues for the years ended June 30 and accounts receivable at June 30 for the indicated time periods below with Minoan: For the years ended 2019 2018 Sales $ 1,405,430 $ 999,719 Accounts receivable $ 221,240 $ 239,062

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes Open tax years related to federal and state income tax filings are for the years ended June 30, 2016, 2017, 2018 and 2019. The Company’s net operating loss carryforwards from closed years can be adjusted by the tax authorities when they are utilized in an open year. The Company files state tax returns in California, Florida, New Jersey, New York, Pennsylvania, Texas and various other states. The Company’s former foreign subsidiary, Misonix Ltd. filed tax return in the United Kingdom and it was dissolved in June 2018. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. There are no uncertain tax positions as defined by ASC 740-10. The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below: June 30, June 30, 2019 2018 Deferred tax assets/(liabilities) Bad debt reserves $ 22,977 $ 45,817 Inventory reserves 238,430 194,363 Accruals and allowances 195,789 18,938 Net operating loss carryforwards 3,875,978 2,738,775 Tax credits 683,659 496,898 Foreign tax credits 401,000 401,000 Stock based compensation 572,378 516,733 Deferred gain - HIFU and Labcaire 92,138 91,862 Amortization (371,940 ) (378,818 ) Depreciation (124,305 ) (36,088 ) Long-term Contract (220,583 ) - Other 9,651 6,873 5,375,172 4,096,353 Valuation Allowance (5,375,172 ) (4,096,353 ) Total net deferred tax assets $ - $ - Tax Cuts and Jobs Act of 2017 The Tax Cuts and Jobs Act of 2017 (the “Tax Legislation”), enacted on December 22, 2017, contains significant changes to U.S. tax law, including lowering the U.S. corporate income tax rate to 21%, implementing a territorial tax system, and imposing a one-time tax on deemed repatriated earnings of foreign subsidiaries. The Tax Legislation reduces the U.S. statutory tax rate from 35% to 21%, effective January 1, 2018. U.S. tax law requires that taxpayers with a fiscal year that begins before and ends after the effective date of a rate change calculate a blended tax rate based on the pro rata number of days in the fiscal year before and after the effective date. As a result, for the fiscal year ended June 30, 2018, the Company’s U.S. statutory income tax rate was 27.55%. On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Legislation. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Legislation enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Legislation for which the accounting under ASC 740 is complete. The Company recorded $1,755,823 discrete tax expense representing the expense of remeasuring its U.S. deferred tax assets at the lower 21% U.S. statutory tax rate. In addition, the Company had approximately $169,000 of alternative minimum tax credit which was reclassified to other current and non-current assets. Valuation Allowance on Deferred Tax Assets Deferred tax assets refer to assets that are attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets in essence represent future savings of taxes that would otherwise be paid in cash. The realization of the deferred tax assets is dependent upon the generation of sufficient future taxable income, including capital gains. If it is determined that the deferred tax assets cannot be realized, a valuation allowance must be established, with a corresponding charge to net income. In accordance with ASC Topic 740, the Company establishes valuation allowances for deferred tax assets that, in its judgment are not more likely-than-not realizable. The guidance requires entities to evaluate all available positive and negative evidence, including cumulative results in recent periods, weighted based on its objectivity, in determining whether its deferred tax assets are more likely than not realizable. The Company regularly assesses its ability to realize its deferred tax assets. The Company is in a three-year cumulative loss position at June 30, 2019, and it expects to be in a cumulative pretax loss position as of June 30, 2020. Management evaluated available positive evidence, including the continued growth of the Company’s revenues and gross profit margins, the completion of the development of its next generation Nexus product, its SonaStar technology license to its Chinese partner and the reduction in investigative and professional fees, along with available negative evidence, including the Company’s continuing investment in building a direct sales force and payment of transaction fees for the Company’s Solsys acquisition. After weighing both the positive and negative evidence, management concluded that the Company’s deferred tax assets are not more likely-than-not realizable. Accordingly, the Company recorded an increase in the valuation allowance for the year ended June 30, 2019 of $1,278,819 against its remaining deferred tax assets at June 30, 2019. The cumulative valuation allowance at June 30, 2019 is $5,375,172. The Company will continue to assess its ability to utilize its net operating loss carryforwards, and will reverse this valuation allowance when sufficient evidence is achieved to allow the realizability of such deferred tax assets. As of June 30, 2019, the Company had approximately $17,178,000 of U.S. federal net operating loss carryforwards of which $10,504,000 will expire in tax years between 2031 and 2037 and $6,674,000 will not expire. Included in U.S. Federal net operating loss carryforward amount are windfall tax benefits related to exercised stock options of approximately $2,491,000, the benefit of which was recorded in equity when the Company adopted ASU 2016-09 beginning in fiscal 2018. The Company has approximately $684,000 of research and development tax credit carryforwards which expire in the tax years between 2026 and 2038. Significant components of the income tax expense (benefit) attributable to continuing operations are as follows: Year Ended June 30, Current: 2019 2018 Federal $ - $ - State 28,547 - Foreign - 401,000 Total current 28,547 401,000 Deferred: Federal - 5,116,778 State - (101,132 ) Total deferred - 5,015,646 $ 28,547 $ 5,416,646 The reconciliation of income tax expense (benefit) computed at the Federal statutory tax rates to income tax expense (benefit) is as follows: Year ended June 30, 2019 2018 Tax at federal statutory rates $ (1,541,883 ) $ (483,207 ) State income taxes, net of federal benefit 22,552 (102,812 ) Research credit (186,761 ) (216,099 ) Stock-based compensation 35,923 306,678 Valuation allowance 1,194,917 4,096,353 Reduction of deferred tax asset related to Tax Legislation - 1,755,823 Meals 25,116 12,458 Transaction Costs 293,256 - Long-term Contracts 201,600 - Other (16,173 ) 47,452 $ 28,547 $ 5,416,646

Employee Profit Sharing Plan

Employee Profit Sharing Plan	12 Months Ended
	Jun. 30, 2019
Employee Profit Sharing Plan [Abstract]
Employee Profit Sharing Plan	10. Employee Profit Sharing Plan The Company sponsors a retirement plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended (the "Code") for all full-time employees. Participants may contribute a percentage of compensation not to exceed the maximum allowed under the Code, which was $24,000 if the employee was over 50 years of age for the year ended June 30, 2019. The plan provides for a matching contribution by the Company of 10% of annual eligible compensation contributed by the participants based on years of service, which amounted to $55,297 and $58,162 for the fiscal years ended June 30, 2019 and 2018, respectively.

Segment Reporting

Segment Reporting	12 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Segment Reporting	11. Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company has concluded that its Chief Executive Officer is the CODM as he is the ultimate decision maker for key operating decisions, determining the allocation of resources and assessing the financial performance of the Company. These decisions, allocations and assessments are performed by the CODM using consolidated financial information. Consolidated financial information is utilized by the CODM as the Company's current product offering primarily consists of minimally invasive therapeutic ultrasonic medical devices. The Company's products are relatively consistent and manufacturing is centralized and consistent across product offerings. Based on these factors, key operating decisions and resource allocations are made by the CODM using consolidated financial data and as such the Company has concluded that it operates as one segment. Worldwide revenue for the Company's products is categorized as follows: For the year ended 2019 2018 Total Consumables $ 28,371,517 $ 23,596,476 Equipment 10,476,974 9,073,350 License - 4,010,000 Total $ 38,848,491 $ 36,679,826 Domestic: Consumables $ 20,561,273 $ 17,735,749 Equipment 2,414,435 2,308,614 License - - Total $ 22,975,708 $ 20,044,363 International: Consumables $ 7,810,244 $ 5,860,727 Equipment 8,062,539 6,764,736 License - 4,010,000 Total $ 15,872,783 $ 16,635,463 Substantially all of the Company's long-lived assets are located in the United States.

Quarterly Results (Unaudited)

Quarterly Results (Unaudited)	12 Months Ended
	Jun. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results (unaudited)	12. Quarterly Results (unaudited) Fiscal 2019 Q1 Q2 Q3 Q4 Year Revenue $ 9,361,164 $ 10,176,453 $ 9,556,590 $ 9,754,284 $ 38,848,491 Cost of goods sold 2,750,543 3,048,079 2,801,571 2,968,146 11,568,339 Gross profit 6,610,621 7,128,374 6,755,019 6,786,138 27,280,152 Operating expenses: Selling expenses 4,735,005 4,800,643 4,414,710 4,393,479 18,343,837 General and administrative expenses 3,183,384 2,347,184 2,512,510 3,835,131 11,878,209 Research and development expenses 1,304,766 839,219 1,426,483 897,501 4,467,969 Total operating expenses 9,223,155 7,987,046 8,353,703 9,126,111 34,690,015 Loss from operations (2,612,534 ) (858,672 ) (1,598,684 ) (2,339,973 ) (7,409,863 ) Other income/(expense): Interest income 19,813 17,242 22,653 30,148 89,856 Other (18,265 ) 1,097 (13,650 ) (7,425 ) (38,243 ) Total other income 1,548 18,339 9,003 22,723 51,613 Loss before income taxes (2,610,986 ) (840,333 ) (1,589,681 ) (2,317,250 ) (7,358,250 ) Income tax expense - - - 28,547 28,547 Net loss $ (2,610,986 ) $ (840,333 ) $ (1,589,681 ) $ (2,345,797 ) $ (7,386,797 ) Net loss per share: Basic $ (0.29 ) $ (0.09 ) $ (0.17 ) $ (0.25 ) $ (0.79 ) Diluted $ (0.29 ) $ (0.09 ) $ (0.17 ) $ (0.25 ) $ (0.79 ) Weighted average shares - Basic 9,100,123 9,322,237 9,390,665 9,428,938 9,333,117 Weighted average shares - Diluted 9,100,123 9,322,237 9,390,665 9,428,938 9,333,117 Fiscal 2018 Q1 Q2 Q3 Q4 Year Revenue Product $ 7,280,723 $ 8,323,845 $ 8,429,132 $ 8,636,126 $ 32,669,826 License - - 4,010,000 - 4,010,000 Total revenue 7,280,723 8,323,845 12,439,132 8,636,126 36,679,826 Cost of goods sold 2,177,355 2,465,826 2,631,893 2,519,824 9,794,898 Gross profit 5,103,368 5,858,019 9,807,239 6,116,302 26,884,928 Operating expenses: Selling expenses 3,570,713 3,919,515 4,447,421 4,430,732 16,368,381 General and administrative expenses 2,573,131 2,380,860 1,925,086 2,184,062 9,063,139 Research and development expenses 901,274 957,204 1,199,895 1,335,776 4,394,149 Total operating expenses 7,045,118 7,257,579 7,572,402 7,950,570 29,825,669 Income (loss) from operations (1,941,750 ) (1,399,560 ) 2,234,837 (1,834,268 ) (2,940,741 ) Other income (expense): Interest income 13 45 9,074 16,991 26,123 Royalty income and license fees 452,971 71,550 916 1 525,438 Other (4,458 ) (4,387 ) (5,712 ) 16,831 2,274 Total other income 448,526 67,208 4,278 33,823 553,835 Loss from continuing operations before income taxes (1,493,224 ) (1,332,352 ) 2,239,115 (1,800,445 ) (2,386,906 ) Income tax expense (benefit) (281,000 ) 5,524,422 - 173,224 5,416,646 Net income (loss) from continuing operations (1,212,224 ) (6,856,774 ) 2,239,115 (1,973,669 ) (7,803,552 ) Income from discontinued operations net of tax - - - 191,117 191,117 Net income (loss) $ (1,212,224 ) $ (6,856,774 ) $ 2,239,115 $ (1,782,552 ) $ (7,612,435 ) Net income (loss) per share: Continuing operations: Basic $ (0.14 ) $ (0.76 ) $ 0.24 $ (0.22 ) $ (0.87 ) Diluted $ (0.14 ) $ (0.76 ) $ 0.23 $ (0.22 ) $ (0.87 ) Discontinued operations Basic $ - $ - $ - $ 0.02 $ 0.02 Diluted $ - $ - $ - $ 0.02 $ 0.02 Combined Basic $ (0.14 ) $ (0.76 ) $ 0.24 $ (0.20 ) $ (0.85 ) Diluted $ (0.14 ) $ (0.76 ) $ 0.23 $ (0.20 ) $ (0.85 ) Weighted average shares - Basic 8,958,405 8,977,984 9,028,506 9,037,046 9,009,189 Weighted average shares - Diluted 8,958,405 8,977,984 9,549,144 9,037,046 9,009,189

Schedule II

Schedule II	12 Months Ended
	Jun. 30, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II	SCHEDULE II Additions Balance at charged Balance at beginning to cost and end of Description of period expenses (Deductions) period Allowance for doubtful accounts As of June 30: 2019 $ 200,000 $ - $ (100,000 ) $ 100,000 2018 $ 96,868 $ 103,132 $ - $ 200,000 Additions Balance at charged (credited) Balance at beginning to cost and end of Description of period expenses (Deductions) period Deferred tax valuation allowance As of June 30: 2019 $ 4,096,353 $ 1,278,819 $ - $ 5,375,172 2018 $ 628,730 $ 3,467,623 $ - $ 4,096,353

Basis of Presentation, Organi_2

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These consolidated financial statements of Misonix, Inc. ("Misonix" or the "Company") include the accounts of Misonix and its 100% owned subsidiaries. All significant intercompany balances and transactions have been eliminated.
Organization and Business	Organization and Business Misonix designs, manufactures, develops and markets therapeutic ultrasonic devices. These products are used for precise bone sculpting, removal of soft tumors, and tissue debridement in the fields of orthopedic surgery, plastic surgery, neurosurgery, podiatry and vascular surgery. In the United States, our products are marketed primarily through a hybrid sales approach. This includes direct sales representatives, managed by regional sales managers, along with independent distributors. Outside the United States, we sell BoneScalpel and SonaStar to specialty distributors who purchase products from us to resell to their clinical customer bases. We sell to all major markets in the Americas, Europe, Middle East, Asia Pacific and Africa. The Company operates as one business segment.
Pending Merger with Solsys Medical, LLC	Pending Merger with Solsys Medical, LLC On May 2, 2019, the Company announced that it has entered into a definitive agreement with Solsys Medical, LLC (“Solsys”), a privately held regenerative medical company, to acquire Solsys in an all-stock transaction valued at approximately $97 million. The planned acquisition of Solsys is expected to substantially broaden Misonix’s addressable market through wound care solutions that are complementary to its existing products. The transaction has been approved by both the Company’s Board of Directors and the Solsys Board of Managers. After the completion of the transaction, it is expected that Misonix shareholders immediately prior to the closing will own 64% of the combined entity, and Solsys unitholders will own 36%. The completion of the acquisition and the issuance of shares in connection with the proposed transaction is subject to the approval by Misonix shareholders and the completion of the transaction is subject to approval by 55% of Solsys’ Series E unitholders and a majority of its Common unitholders, Series A unitholders, Series B unitholders, Series C unitholders and Series D unitholders, voting as a single class, as well as the satisfaction of certain customary closing conditions. The Company will convene a special shareholder meeting to vote on the transaction. The Company anticipates that the transaction will close in the third quarter of calendar year 2019. Professional fees incurred during the year ended June 30, 2019 with respect to this matter were approximately $1.9 million. Approximately $539,000 of these costs relate to the registration of the common stock that will be issued to pay for the transaction. These costs are included in Intangible and other assets as of June 30, 2019 and will be applied against Additional paid-in capital upon closing of the transaction.
High Intensity Focused Ultrasound Technology	High Intensity Focused Ultrasound Technology The Company sold its rights to the high intensity focused ultrasound technology to SonaCare Medical, LLC ("SonaCare") in May 2010. The Company may receive up to approximately $5.8 million in payment for the sale. SonaCare is required to pay the Company 7% of the gross revenues received from its sales of the (i) prostate product in Europe and (ii) kidney and liver products worldwide, until the Company has received payments of $3 million, and thereafter 5% of the gross revenues, up to an aggregate payment of $5.8 million, all subject to a minimum annual royalty of $250,000. Cumulative payments through June 30, 2019 were $2,542,579. SonaCare has defaulted on its royalty payment due on March 31, 2019, and the Company is in discussions with SonaCare regarding this default. Given that the payment is uncertain, the Company has not recorded any income relating to this payment.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. All of the Company's cash is maintained in bank accounts and accordingly it does not have cash equivalents at June 30, 2019. The Company's cash balance at June 30, 2019 was $7,842,403. The Company maintains cash balances at various financial institutions. At June 30, 2019, these financial institutions held cash that was approximately $4,366,000 in excess of amounts insured by the Federal Deposit Insurance Corporation and other government agencies.
Major Customers and Concentration of Credit Risk	Major Customers and Concentration of Credit Risk Included in sales from continuing operations are sales to the Company distributor of SonaStar in China of $151,949 and $6,969,258 for the fiscal years ended June 30, 2019 and 2018, respectively, inclusive of product licensing fees of $4,010,000. Accounts receivable from this customer were $14,850 at June 30, 2019. Also included in sales from continuing operations are sales to the Company's distributor of its BoneScalpel product in China of $4,473,534 and $0 for the fiscal years ended June 30, 2019 and 2018, respectively. Accounts receivable from this customer were $493,784 at June 30, 2019. Total royalties from Medtronic Minimally Invasive Therapies ("MMIT") related to its sales of the Company's ultrasonic cutting and sculpting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $0 and $525,000 for the fiscal years ended June 30, 2019 and 2018, respectively. There were no accounts receivable from MMIT royalties at June 30, 2019 and 2018, respectively. The license agreement with MMIT expired in August 2017. At June 30, 2019 and 2018, the Company's accounts receivable with customers outside the United States were approximately $2,181,000 and $1,630,000, respectively, none of which is over 90 days.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for but not limited to establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and related valuation allowances, and stock-based compensation. Actual results could differ from those estimates.
Accounts Receivable	Accounts Receivable Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist of raw materials, work-in process and finished goods and include purchased materials, direct labor and manufacturing overhead. Management evaluates the need to record adjustments to write down inventory to the lower of cost or net realizable value on a quarterly basis. The Company's policy is to assess the valuation of all inventories, including raw materials, work-in-process and finished goods and it writes down its inventory for estimated obsolescence based upon the age of inventory and assumptions about future demand and usage. Inventory items used for demonstration purposes, rentals or on consignment are classified as property, plant and equipment.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are recorded at cost. Minor replacements and maintenance and repair expenses are charged to expense as incurred. Depreciation of property and equipment is provided using the straight-line method over estimated useful lives ranging from 3 to 5 years. Leasehold improvements are amortized over the life of the lease or the useful life of the related asset, whichever is shorter. The Company's policy is to periodically evaluate the appropriateness of the lives assigned to property, plant and equipment and make adjustments if necessary. Depreciation of BoneScalpel and SonicOne generators which are consigned to customers are depreciated over a 5- year period, and depreciation is charged to selling expenses. See Note 4.
Revenue Recognition	Revenue Recognition On July 1, 2018 the Company adopted Accounting Standards Codification ("ASC") Topic 606 "Revenue from Contracts with Customers, as amended" ("ASC Topic 606"), using the modified retrospective method applied to those contracts which were not completed as of the adoption date. The reported results for year ended June 30, 2019 reflect the application of Topic 606 guidance while the reported results for fiscal year 2018 were prepared under the guidance of ASC Topic 605, "Revenue Recognition". The adoption of ASC Topic 606 resulted in a cumulative prior period adjustment in the amount of $960,000 related to the Company's License and Exclusive Manufacturing Agreement described below, but the remainder of the adoption did not have a material impact on the timing or amount of revenue recognized. The impacts of adopting ASC Topic 606 on the Company's consolidated balance sheets as of July 1, 2018 were as follows: As Adjusted As ASC 606 Under Reported Adjustments ASC 606 Long-term contract assets $ - $ 960,000 $ 960,000 Total Shareholders' equity $ 24,401,178 $ 960,000 $ 25,361,178 The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC Topic 606: 1) the Company accounts for amounts collected from customers for sales and other taxes net of related amounts remitted to tax authorities; 2) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 3) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling, general and administrative expenses; 4) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer; 5) the Company will utilize the right-to-invoice practical expedient with regard to the recognition of revenue upon the purchase of consumable goods in connection with a product placement/consignment arrangement. The Company determines revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, a performance obligation is satisfied Contracts and Performance Obligations The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and related services identified in the contracts, purchase orders or invoices. For each contract, the Company considers the obligation to transfer products or bundled products and services to the customer, of which each is distinct in the context of the contract, to be performance obligations. The Company historically has not made provisions for returns and allowances as they have not been material to the operations of the Company. Transaction Price and Allocation to Performance Obligations Transaction prices of products are typically based upon contracted rates as specified on the purchase order for the purchase of consumables. The Company's contracted rates represent the standalone selling price of a consumable which is generally determined through the sale of products and/or bundled products or services separately in similar circumstances to similar customers. The Company determines the effects of variable consideration, inclusive of any constraints, in determining the transaction price with regard to its contracts with customers. Recognition of Revenue The Company satisfies performance obligations either over time, or at a point in time, upon which control transfers to the customer. Revenue derived from the shipping and billing of product is recorded upon shipment, when transfer of control occurs for products shipped freight on board ("F.O.B.") shipping point. Products shipped F.O.B. destination point are recorded as revenue when received at the point of destination when the transfer of control is completed. Shipments under agreements with distributors are not subject to return, and payment for these shipments is not contingent on sales by the distributor. Accordingly, the Company recognizes revenue on shipments to distributors in the same manner as with other customers under the ship and bill process. Revenue derived from the rental of equipment is recorded on a monthly basis over the term of the lease. Shipments of consumable products to these rental customers is recorded as orders are received and shipments are made F.O.B. destination or F.O.B. shipping point. Revenue derived from consignment agreements is earned as consumables product orders are fulfilled using the right to invoice practical expedient. Therefore, revenue is recognized as control passes to the customer, which is typically when shipments are made F.O B shipping point or F.O.B destination. Revenue derived from service and maintenance contracts is recognized evenly over the life of the service agreement as the services are performed. Contract Specific Performance Obligations and Significant Judgements Product Placement/Consignment Agreements The Company's product placement/consignment agreements provide for the placement of a generator at the customer's place of business and set pricing related to the purchase of consumables for use in conjunction with the generator. These agreements do not require any minimum consumable purchase quantities and do not have a stated term. The Company considers the transaction price in these arrangements to be fully constrained variable consideration because it is dependent on future sales of consumables to the customer. The Company has determined that the pattern of purchase of consumables by a customer is consistent with the benefit received by the customer for the use of the generator and therefore the Company has a right to consideration based upon the pattern of consumable purchases placed through purchase orders by the customer. The Company's invoices to these customers have short-term payment terms and are aligned with the transfer of goods and services to the customer and the Company recognizes revenue based upon its right to invoice customers. License and Manufacturing Agreement On October 19, 2017, the Company entered into a License and Exclusive Manufacturing Agreement (the "L&M Agreement") with Hunan Xing Hang Rui Kang Bio-technologies Co., Ltd, a Chinese corporation (the "Licensee") under which Misonix has licensed certain manufacturing and distribution rights to its SonaStar product line in China, Hong Kong and Macau. The Licensee was obligated to make an initial payment of $5,000,000 for the transfer of functional intellectual property and initial stocking orders of product. In addition, the Licensee is required to make minimum royalty payments of $2,000,000 per calendar year for three years beginning in 2019, based upon the manufacture of products by the Licensee. The Company collected $5,000,000 of initial revenue for the quarter ended March 31, 2018 under ASC 605. Upon the adoption of ASC Topic 606, the Company evaluated this contract under the provisions of the new revenue standard. The Company determined that the satisfied performance obligations and allocation of the transaction price related to the $5,000,000 received prior to adoption was consistent with the provisions of ASC Topic 606 and also recorded a transitional adjustment to accumulated deficit in the amount of $960,000 as follows: Minimum royalty revenue provided by the contract $ 6,000,000 Implicit price concession (5,040,000 ) Adoption adjustment to accumulated deficit under ASC 606 $ 960,000 Although the contract includes minimum royalties, the Company concluded that a significant portion of those guaranteed minimums are actually variable consideration subject to the constraint because the Company has provided an implicit price concession. Specifically, the fact that production of the product in China is not assured and the Licensee must develop a manufacturing process, coupled with the fact that new technology related to the product is expected to be available for sale domestically, may result in the Licensee not earning sufficient revenue in order to pay the minimum royalties. Therefore, the Company has determined variable consideration through utilization of the most likely method based upon forecasts and projections of shipment of products. The Company will monitor facts and circumstances over time and adjust management's most likely estimate of variable consideration on a quarterly basis. As of June 30, 2019, the Company updated its estimate and concluded the amount is not materially different. The uncertainties that existed at inception of the contract still exist at June 30, 2019. Disaggregation of Revenue The Company generates revenue from the sale and leasing of medical equipment and from the sale of consumable products used with medical equipment in surgical procedures as well as through product licensing arrangements. In the United States, the Company's products are marketed primarily through a hybrid sales approach which includes direct sales representatives, managed by regional sales managers, along with independent distributors. Outside the United States, the Company sells BoneScalpel and SonaStar to specialty distributors who purchase products to resell to their clinical customer bases. The Company sells to all major markets in the Americas, Europe, Middle East, Asia Pacific, and Africa. Revenue is disaggregated from contracts between products under ship and bill arrangements and licensing agreements, and by geography, which the Company believes best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. The Company also provides an immaterial amount of service revenue which is recognized over time, but not stated separately because the amounts are immaterial. The following table disaggregates the Company's product revenue by classification and geographic location: For the year ended 2019 2018 Total Consumables $ 28,371,517 $ 23,596,476 Equipment 10,476,974 9,073,350 Total Product 38,848,491 32,669,826 License Fee - 4,010,000 Total $ 38,848,491 $ 36,679,826 Domestic: Consumables $ 20,561,273 $ 17,735,749 Equipment 2,414,435 2,308,614 Total $ 22,975,708 $ 20,044,363 International: Consumables $ 7,810,244 $ 5,860,727 Equipment 8,062,539 6,764,736 Total $ 15,872,783 $ 12,625,463 Contract Assets The timing of revenue recognition, customer invoicing, and collections produces accounts receivable and contract assets on the Company's consolidated balance sheet. Contract liabilities are not material to the operations of the Company as of June 30, 2019. The Company invoices in accordance with contract payment terms. Invoices to customers represent an unconditional right of the Company to receive consideration. When revenue is recognized in advance of customer invoicing a contract asset is recorded. Unpaid customer invoices are reflected as accounts receivable. The Company has established a contract asset in conjunction with the Company's L&M Agreement based upon its assessment of the most likely variable consideration to be received by the Company as a result of the royalty provisions in the contract. The asset is recorded as a long-term asset as the Company believes that payment will be made on this asset in a duration exceeding one year. Contract assets as of June 30, 2019 and June 30, 2018 were $960,000 and $0, respectively. Selling Costs Incremental direct costs of obtaining a sales contract primarily include sales commissions paid to sales personnel and outside sales representatives in connection with sales of products under ship and bill scenarios or through product placement scenarios. The expected period of benefit of these costs is one year or less and therefore the Company has elected the practical expedient to expense such costs in the period in which they are incurred. Typically, costs in fulfilling a contract represent shipping and handling costs and the Company accounts for these costs as fulfillment costs and they are expensed as incurred. Costs in fulfilling a contract are only capitalized as an asset if they relate directly to an existing contract or specific anticipated contract, they generate or enhance resources of the entity that will be used to satisfy performance obligations in the future, and they are expected to be recovered. The Company has not identified any such costs.
Long-Lived Assets	Long-Lived Assets The carrying values of intangible and other long-lived assets, excluding goodwill, are periodically reviewed to determine if any impairment indicators are present. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization and depreciation period, their carrying values are reduced to estimated fair value. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated decline in revenue or operating profit, adverse legal or regulatory developments, accumulation of costs significantly in excess of amounts originally expected to acquire the asset and a material decrease in the fair value of some or all of the assets. Assets are grouped at the lowest levels for which there are identifiable cash flows that are largely independent of the cash flows generated by other asset groups. No such impairment was deemed to exist in fiscal 2019 and 2018.
Goodwill	Goodwill Goodwill is not amortized. The Company reviews goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of this impairment test requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company's business, the useful lives over which cash flows will occur and determination of the Company's weighted average cost of capital. The Company also compares its market capitalization to the value of its goodwill to view for evidence of impairment. The Company completed its annual goodwill impairment tests for fiscal 2019 and 2018 as of March 31 of each year. No impairment of goodwill was deemed to exist in fiscal 2019 and 2018.
Patents	Patents The cost of acquiring or processing patents is capitalized at cost. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Patents totaled $779,100 and $757,447 at June 30, 2019 and 2018, respectively. Amortization expense for the years ended June 30, 2019 and 2018 was approximately $141,200 and $127,000, respectively. The following is a schedule of estimated future patent amortization expense as of June 30, 2019 during the following fiscal years: 2020 $ 120,186 2021 112,993 2022 75,332 2023 74,241 2024 66,486 Thereafter 329,862 $ 779,100
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible. Should management determine that it is more likely than not that some portion of the deferred tax asset will not be realized, a valuation allowance against the deferred tax asset would be established in the period such determination was made. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company classifies income tax related interest and penalties as a component of income tax expense.
Earnings Per Share	Earnings Per Share Earnings per share ("EPS") is calculated using the two class method, which allocates earnings among common stock and participating securities to calculate EPS when an entity's capital structure includes either two or more classes of common stock or common stock and participating securities. Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities. As such, unvested shares of restricted stock of the Company are considered participating securities. The dilutive effect of options and their equivalents (including non-vested stock issued under stock based compensation plans), is computed using the "treasury" method. Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding: For the years ended 2019 2018 Basic weighted average shares outstanding 9,333,117 9,009,189 Dilutive effect of restricted stock awards (participating securities) - - Denominator for basic earnings per share 9,333,117 9,009,189 Dilutive effect of stock options - - Diluted weighted average shares outstanding 9,333,117 9,009,189 Diluted EPS for the years ended June 30, 2019 and 2018 as presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. Accordingly, excluded from the calculation of diluted EPS are the dilutive effect of options to purchase 482,926 and 211,801 shares of common stock for the years ended June 30, 2019 and 2018, respectively. Also excluded from the calculation of both basic and diluted earnings per share for the years ended June 30, 2019 and 2018 are the 400,000 shares of restricted common stock which were issued in December 2016.
Research and Development	Research and Development All research and development expenses are expensed as incurred and are included in operating expenses.
Advertising Expense	Advertising Expense The cost of advertising is expensed in the period the advertising first takes place. The Company incurred approximately $47,000, and $0 in advertising costs during the fiscal years ended June 30, 2019 and 2018, respectively. Advertising costs are reported in selling expenses on the statement of operations.
Depreciation Expense for Consigned Inventory	Depreciation Expense for Consigned Inventory The Company typically provides to its United States customers, on a consignment basis, the generators used to power its BoneScalpel and SonicOne products. Title to these generators remains at all times with the Company. When these generators are deployed in the field at customer locations, the Company depreciates these units over a five-year period and charges the depreciation to selling expenses. Depreciation expense relating to consigned generators and for demonstration equipment for the years ended June 30, 2019 and 2018 was $1,093,000 and $923,000, respectively.
Shipping and Handling	Shipping and Handling Shipping and handling fees for the fiscal years ended June 30, 2019 and 2018 were approximately $83,000 and $99,000, respectively, and are reported as a component of net sales. Shipping and handling costs for the fiscal years ended June 30, 2019 and 2018 were approximately $563,000 and $289,000, respectively, and are reported as a component of selling expenses.
Stock-Based Compensation	Stock-Based Compensation The Company measures compensation cost for all share based payments at fair value and recognizes the cost over the vesting period. The Company uses the Black-Scholes method to value awards and utilizes the straight line amortization method to recognize the expense associated with the awards with graded vesting terms.
Restricted Stock Awards	Restricted Stock Awards The Company measures compensation cost for all restricted stock awards at fair value and recognizes the cost over the vesting period. For awards that have market conditions, the Company uses the Monte Carlo valuation method to value awards and utilizes the straight line amortization method to recognize the expense associated with the awards with graded vesting terms. Where awards have performance conditions, the Company will determine the probability of achieving those conditions and will record compensation expense when it is probable that the conditions will be met.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instrument. ASU 2016-13 replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for SEC filers for interim and annual periods beginning after December 15, 2019. Management is currently assessing the impact ASU 2016-13 will have on the Company, but it is not expected to have a material impact on the Company's financial statements. There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), and has since issued amendments thereto, related to the accounting for leases (collectively referred to as "ASC 842"). ASC 842 establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The Company will adopt ASC 842 on July 1, 2019. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Entities have the option to continue to apply historical accounting under Topic 840, including its disclosure requirements, in comparative periods presented in the year of adoption. An entity that elects this option will recognize a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption instead of the earliest period presented. The Company expects to elect to apply the optional ASC 842 transition provisions beginning on July 1, 2019. Accordingly, the Company will continue to apply Topic 840 prior to July 1, 2019, including Topic 840 disclosure requirements, in the comparative periods presented. The Company expects to elect the package of practical expedients for all its leases that commenced before July 1, 2019. The Company has evaluated its real estate lease, its copier leases and its generator rental agreements. The Company expects that the adoption of ASC 842 will materially impact its balance sheet and have an immaterial impact on its results of operations. Based on the Company's current agreements, the Company expects that upon the adoption of ASC 842 on July 1, 2019, it will record an operating lease liability of approximately $400,000 and corresponding ROU assets based on the present value of the remaining minimum rental payments associated with the Company's leases. As the Company's leases do not provide an implicit rate, nor is one readily available, the Company will use its incremental borrowing rate based on information available at July 1, 2019 to determine the present value of its future minimum rental payments. In March 2016, the FASB issued Accounting Standards Update No. 2016-09 "Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" intended to simplify several aspects of accounting for share-based payment transactions. The Company adopted these amendments beginning in the first quarter of fiscal 2018. The guidance requires that all excess tax benefits and tax deficiencies previously recorded as additional paid-in capital be prospectively recorded in income tax expense. The guidance allows for an increase in the threshold for net share settlement up to the maximum statutory rate in employees' applicable jurisdictions without triggering liability classification. The adoption of this guidance had an immaterial impact on income taxes on the Company's Consolidated Statement of Operations for the year ended June 30, 2018. The Company elected to apply the presentation requirement for cash flows related to excess tax benefits prospectively, which had an immaterial impact on both net cash from operating activities and net cash used in financing activities for the year ended June 30, 2018. The presentation requirements for cash flows related to employee taxes paid for withheld shares had no impact on any of the periods presented on the Company's Consolidated Statements of Cash Flows since such cash flows have historically been presented as a financing activity. Finally, the Company has elected to account for forfeitures as they occur, rather than estimate expected forfeitures. As a result, the Company recorded the cumulative impact of $908,875 as an increase to Deferred Income Taxes with a corresponding decrease to Accumulated Deficit.

Basis of Presentation, Organi_3

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Schedule of impacts of adopting ASC Topic 606	As Adjusted As ASC 606 Under Reported Adjustments ASC 606 Long-term contract assets $ - $ 960,000 $ 960,000 Total Shareholders' equity $ 24,401,178 $ 960,000 $ 25,361,178
Schedule of transitional adjustment to accumulated deficit	Minimum royalty revenue provided by the contract $ 6,000,000 Implicit price concession (5,040,000 ) Adoption adjustment to accumulated deficit under ASC 606 $ 960,000
Schedule of classification and geographic location	For the year ended 2019 2018 Total Consumables $ 28,371,517 $ 23,596,476 Equipment 10,476,974 9,073,350 Total Product 38,848,491 32,669,826 License Fee - 4,010,000 Total $ 38,848,491 $ 36,679,826 Domestic: Consumables $ 20,561,273 $ 17,735,749 Equipment 2,414,435 2,308,614 Total $ 22,975,708 $ 20,044,363 International: Consumables $ 7,810,244 $ 5,860,727 Equipment 8,062,539 6,764,736 Total $ 15,872,783 $ 12,625,463
Schedule of estimated future patent amortization expense	2020 $ 120,186 2021 112,993 2022 75,332 2023 74,241 2024 66,486 Thereafter 329,862 $ 779,100
Schedule of weighted average shares outstanding and diluted weighted average shares outstanding	For the years ended 2019 2018 Basic weighted average shares outstanding 9,333,117 9,009,189 Dilutive effect of restricted stock awards (participating securities) - - Denominator for basic earnings per share 9,333,117 9,009,189 Dilutive effect of stock options - - Diluted weighted average shares outstanding 9,333,117 9,009,189

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of inventories	June 30, June 30, Raw material $ 4,830,207 $ 3,540,205 Work-in-process 224,252 180,442 Finished goods 2,743,361 1,743,497 7,797,820 5,464,144 Less valuation reserve (444,258 ) (444,258 ) $ 7,353,562 $ 5,019,886

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	June 30, June 30, Demonstration and consignment inventory $ 9,076,970 $ 8,227,878 Machinery and equipment 2,793,908 2,582,244 Furniture and fixtures 1,471,371 1,464,325 Leasehold improvements 691,751 691,751 Software systems 688,203 223,087 Automobiles 22,328 22,328 14,744,531 13,211,613 Less: accumulated depreciation and amortization (10,545,810 ) (9,023,235 ) $ 4,198,721 $ 4,188,378

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	June 30, June 30, 2019 2018 Accrued payroll, payroll taxes and vacation $ 488,339 $ 351,435 Accrued bonus 622,115 552,988 Accrued commissions 662,007 742,807 Professional fees 181,313 102,065 Deferred foreign vendor taxes (1) - 401,000 Vendor, tax and other accruals 534,740 661,877 $ 2,488,514 $ 2,812,172 (1) Reclassified to non-current liabilities in fiscal 2019

Stock-Based Compensation Plans

Stock-Based Compensation Plans (Tables)	12 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of stock-based compensation plans	Plan Initial Granted Exercised Expired / Forfeited Outstanding Available 2001 Employee Stock Option Plan 1,000,000 1,251,261 376,368 869,455 5,438 - 2005 Employee Equity Incentive Plan 500,000 547,125 494,200 48,925 4,000 - 2005 Non Employee Director Stock Option Plan 500,000 195,000 127,500 52,500 15,000 - 2009 Employee Equity Incentive Plan 500,000 624,925 399,407 129,350 96,168 - 2009 Non Employee Director Stock Option Plan 200,000 230,000 60,000 56,250 113,750 4,425 2012 Employee Equity Incentive Plan 500,000 732,000 190,999 242,501 298,500 10,501 2012 Non Employee Director Stock Option Plan 200,000 237,500 37,500 56,250 143,750 18,750 2014 Employee Equity Incentive Plan 750,000 945,000 81,874 223,876 639,250 28,876 2017 Equity Incentive Plan 750,000 285,000 - 37,000 248,000 499,000 Total 1,563,856 561,552
Schedule of weighted average fair value at date of grant for options	For the years ended 2019 2018 Risk-free interest rates 2.80 % 1.98 % Expected option life in years 6.25 5.95 Expected stock price volatility 56.01 % 57.42 % Expected dividend yield 0 % 0 %
Schedule of option activity	Options Outstanding Weighted Average Exercise Aggregate Vested and exercisable at June 30, 2017 517,361 $ 6.33 $ 1,923,794 Granted 305,500 10.10 Exercised (76,418 ) 5.47 Forfeited (15,125 ) 7.89 Expired (75,000 ) 4.87 Outstanding as of June 30, 2018 1,330,193 $ 8.47 $ 5,369,557 Vested and exercisable at June 30, 2018 681,316 $ 7.67 $ 3,355,240 Granted 255,000 16.64 Exercised (245,835 ) 7.96 Forfeited (160,502 ) 10.15 Expired (15,000 ) 2.66 Outstanding as of June 30, 2019 1,163,856 $ 10.28 $ 17,617,231 Vested and exercisable at June 30, 2019 656,730 $ 8.42 $ 11,162,650
Schedule of stock options outstanding and exercisable	Options Outstanding Options Exercisable Weighted Average Weighted Weighted Range of Contractual Average Average Exercise Prices Life Exercise Exercise Low High Number (Yrs.) Price Number Price $ 1.82 - $ 6.98 225,106 4.6 $ 4.89 183,606 $ 4.47 $ 6.99 - $ 9.45 237,125 5.9 $ 8.21 197,249 $ 8.14 $ 9.46 - $ 10.23 246,125 7.9 $ 9.84 124,625 $ 9.74 $ 10.24 - $ 13.35 223,500 6.9 $ 11.75 149,250 $ 12.49 $ 13.36 - $ 19.84 232,000 9.3 $ 16.70 2,000 $ 13.89 1,163,856 6.9 $ 10.28 656,730 $ 8.42

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments	Operating Leases 2020 $ 365,942 2021 96,517 Total mimimun lease payments $ 462,459

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Schedule of net sales and accounts receivables	For the years ended 2019 2018 Sales $ 1,405,430 $ 999,719 Accounts receivable $ 221,240 $ 239,062

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities	June 30, June 30, 2019 2018 Deferred tax assets/(liabilities) Bad debt reserves $ 22,977 $ 45,817 Inventory reserves 238,430 194,363 Accruals and allowances 195,789 18,938 Net operating loss carryforwards 3,875,978 2,738,775 Tax credits 683,659 496,898 Foreign tax credits 401,000 401,000 Stock based compensation 572,378 516,733 Deferred gain - HIFU and Labcaire 92,138 91,862 Amortization (371,940 ) (378,818 ) Depreciation (124,305 ) (36,088 ) Long-term Contract (220,583 ) - Other 9,651 6,873 5,375,172 4,096,353 Valuation Allowance (5,375,172 ) (4,096,353 ) Total net deferred tax assets $ - $ -
Schedule of significant components of the income tax expense (benefit)	Year Ended June 30, Current: 2019 2018 Federal $ - $ - State 28,547 - Foreign - 401,000 Total current 28,547 401,000 Deferred: Federal - 5,116,778 State - (101,132 ) Total deferred - 5,015,646 $ 28,547 $ 5,416,646
Schedule of reconciliation of income tax expense (benefit)	Year ended June 30, 2019 2018 Tax at federal statutory rates $ (1,541,883 ) $ (483,207 ) State income taxes, net of federal benefit 22,552 (102,812 ) Research credit (186,761 ) (216,099 ) Stock-based compensation 35,923 306,678 Valuation allowance 1,194,917 4,096,353 Reduction of deferred tax asset related to Tax Legislation - 1,755,823 Meals 25,116 12,458 Transaction Costs 293,256 - Long-term Contracts 201,600 - Other (16,173 ) 47,452 $ 28,547 $ 5,416,646

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Schedule of revenue	For the year ended 2019 2018 Total Consumables $ 28,371,517 $ 23,596,476 Equipment 10,476,974 9,073,350 License - 4,010,000 Total $ 38,848,491 $ 36,679,826 Domestic: Consumables $ 20,561,273 $ 17,735,749 Equipment 2,414,435 2,308,614 License - - Total $ 22,975,708 $ 20,044,363 International: Consumables $ 7,810,244 $ 5,860,727 Equipment 8,062,539 6,764,736 License - 4,010,000 Total $ 15,872,783 $ 16,635,463

Quarterly Results (Unaudited) (

Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule of quarterly results	Fiscal 2019 Q1 Q2 Q3 Q4 Year Revenue $ 9,361,164 $ 10,176,453 $ 9,556,590 $ 9,754,284 $ 38,848,491 Cost of goods sold 2,750,543 3,048,079 2,801,571 2,968,146 11,568,339 Gross profit 6,610,621 7,128,374 6,755,019 6,786,138 27,280,152 Operating expenses: Selling expenses 4,735,005 4,800,643 4,414,710 4,393,479 18,343,837 General and administrative expenses 3,183,384 2,347,184 2,512,510 3,835,131 11,878,209 Research and development expenses 1,304,766 839,219 1,426,483 897,501 4,467,969 Total operating expenses 9,223,155 7,987,046 8,353,703 9,126,111 34,690,015 Loss from operations (2,612,534 ) (858,672 ) (1,598,684 ) (2,339,973 ) (7,409,863 ) Other income/(expense): Interest income 19,813 17,242 22,653 30,148 89,856 Other (18,265 ) 1,097 (13,650 ) (7,425 ) (38,243 ) Total other income 1,548 18,339 9,003 22,723 51,613 Loss before income taxes (2,610,986 ) (840,333 ) (1,589,681 ) (2,317,250 ) (7,358,250 ) Income tax expense - - - 28,547 28,547 Net loss $ (2,610,986 ) $ (840,333 ) $ (1,589,681 ) $ (2,345,797 ) $ (7,386,797 ) Net loss per share: Basic $ (0.29 ) $ (0.09 ) $ (0.17 ) $ (0.25 ) $ (0.79 ) Diluted $ (0.29 ) $ (0.09 ) $ (0.17 ) $ (0.25 ) $ (0.79 ) Weighted average shares - Basic 9,100,123 9,322,237 9,390,665 9,428,938 9,333,117 Weighted average shares - Diluted 9,100,123 9,322,237 9,390,665 9,428,938 9,333,117 Fiscal 2018 Q1 Q2 Q3 Q4 Year Revenue Product $ 7,280,723 $ 8,323,845 $ 8,429,132 $ 8,636,126 $ 32,669,826 License - - 4,010,000 - 4,010,000 Total revenue 7,280,723 8,323,845 12,439,132 8,636,126 36,679,826 Cost of goods sold 2,177,355 2,465,826 2,631,893 2,519,824 9,794,898 Gross profit 5,103,368 5,858,019 9,807,239 6,116,302 26,884,928 Operating expenses: Selling expenses 3,570,713 3,919,515 4,447,421 4,430,732 16,368,381 General and administrative expenses 2,573,131 2,380,860 1,925,086 2,184,062 9,063,139 Research and development expenses 901,274 957,204 1,199,895 1,335,776 4,394,149 Total operating expenses 7,045,118 7,257,579 7,572,402 7,950,570 29,825,669 Income (loss) from operations (1,941,750 ) (1,399,560 ) 2,234,837 (1,834,268 ) (2,940,741 ) Other income (expense): Interest income 13 45 9,074 16,991 26,123 Royalty income and license fees 452,971 71,550 916 1 525,438 Other (4,458 ) (4,387 ) (5,712 ) 16,831 2,274 Total other income 448,526 67,208 4,278 33,823 553,835 Loss from continuing operations before income taxes (1,493,224 ) (1,332,352 ) 2,239,115 (1,800,445 ) (2,386,906 ) Income tax expense (benefit) (281,000 ) 5,524,422 - 173,224 5,416,646 Net income (loss) from continuing operations (1,212,224 ) (6,856,774 ) 2,239,115 (1,973,669 ) (7,803,552 ) Income from discontinued operations net of tax - - - 191,117 191,117 Net income (loss) $ (1,212,224 ) $ (6,856,774 ) $ 2,239,115 $ (1,782,552 ) $ (7,612,435 ) Net income (loss) per share: Continuing operations: Basic $ (0.14 ) $ (0.76 ) $ 0.24 $ (0.22 ) $ (0.87 ) Diluted $ (0.14 ) $ (0.76 ) $ 0.23 $ (0.22 ) $ (0.87 ) Discontinued operations Basic $ - $ - $ - $ 0.02 $ 0.02 Diluted $ - $ - $ - $ 0.02 $ 0.02 Combined Basic $ (0.14 ) $ (0.76 ) $ 0.24 $ (0.20 ) $ (0.85 ) Diluted $ (0.14 ) $ (0.76 ) $ 0.23 $ (0.20 ) $ (0.85 ) Weighted average shares - Basic 8,958,405 8,977,984 9,028,506 9,037,046 9,009,189 Weighted average shares - Diluted 8,958,405 8,977,984 9,549,144 9,037,046 9,009,189

Basis of Presentation, Organi_4

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Long-term contract assets	$ 960,000
Total Shareholders' equity	21,704,049	$ 24,401,178	$ 28,139,842
ASC 606 Adjustments [Member]
Finite-Lived Intangible Assets [Line Items]
Long-term contract assets	960,000
Total Shareholders' equity	960,000
As Reported [Member
Finite-Lived Intangible Assets [Line Items]
Long-term contract assets
Total Shareholders' equity	24,401,178
As Adjusted Under ASC 606 [Member]
Finite-Lived Intangible Assets [Line Items]
Long-term contract assets	960,000
Total Shareholders' equity	$ 25,361,178

Basis of Presentation, Organi_5

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 1)	Jun. 30, 2019USD ($)
License and Manufacturing Agreement
Minimum royalty revenue provided by the contract	$ 6,000,000
Implicit price concession	(5,040,000)
Adoption adjustment to accumulated deficit under ASC 606	$ 960,000

Basis of Presentation, Organi_6

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Domestic [Member]
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue	$ 22,975,708	$ 20,044,363
International [Member]
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue	15,872,783	12,625,463
Consumables [Member] | Domestic [Member]
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue	20,561,273	17,735,749
Consumables [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue	7,810,244	5,860,727
Equipment [Member] | Domestic [Member]
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue	2,414,435	2,308,614
Equipment [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue	8,062,539	6,764,736
Product [Member]
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue	38,848,491	36,679,826
License		4,010,000
Total Product	38,848,491	32,669,826
Product [Member] | Consumables [Member]
Disaggregation of Revenue [Abstract]
Total Product	28,371,517	23,596,476
Product [Member] | Equipment [Member]
Disaggregation of Revenue [Abstract]
Total Product	$ 10,476,974	$ 9,073,350

Basis of Presentation, Organi_7

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 3) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Total	$ 779,100	$ 757,447
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2020	120,186
2021	112,993
2022	75,332
2023	74,241
2024	66,486
Thereafter	329,862
Total	$ 779,100

Basis of Presentation, Organi_8

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 4) - shares	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Accounting Policies [Abstract]
Basic weighted average shares outstanding									9,333,117	9,009,189
Dilutive effect of restricted stock awards (participating securities)
Denominator for basic earnings per share	9,428,938	9,390,665	9,322,237	9,100,123	9,037,046	9,028,506	8,977,984	8,958,405	9,333,117	9,009,189
Dilutive effect of stock options
Diluted weighted average shares outstanding	9,428,938	9,390,665	9,322,237	9,100,123	9,037,046	9,549,144	8,977,984	8,958,405	9,333,117	9,009,189

Basis of Presentation, Organi_9

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details Textual)	May 02, 2019USD ($)	Oct. 19, 2017USD ($)Number	May 10, 2010USD ($)	Dec. 31, 2016shares	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2019USD ($)Segmentshares	Jun. 30, 2018USD ($)shares	Jul. 01, 2019USD ($)
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Ownership percentage					100.00%								100.00%
Number of operating segment | Segment													1
Cash and cash equivalents					$ 7,842,403				$ 10,979,455				$ 7,842,403	$ 10,979,455
Cash held uninsured amount									4,366,000					4,366,000
Sales from continuing operations					9,754,284	$ 9,556,590	$ 10,176,453	$ 9,361,164	8,636,126	$ 12,439,132	$ 8,323,845	$ 7,280,723	38,848,491	36,679,826
Accounts receivable					5,360,454				5,245,549				$ 5,360,454	$ 5,245,549
Estimated useful lives													30-06-2021
Dilutive effect of options to purchase shares of common stock | shares													482,926	211,801
Advertising expense													$ 47,000	$ 0
Shipping and handling fees					2,968,146	$ 2,801,571	$ 3,048,079	$ 2,750,543	2,519,824	2,631,893	2,465,826	2,177,355	11,568,339	9,794,898
Deferred tax asset					960,000				0				960,000	0
Percentage of Ownership before Transaction	64.00%
Professional fees													1,900,000
Revenue Recognition amount					960,000								960,000
Revenue from distributors													151,949	6,969,258
Costs relate to registration of common stock													539,000
Cumlative impact														908,875
BoneScapel Generators [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Intangible assets estimated useful lives													5 years
Depreciation expense														923,000
Revenue from distributors													$ 4,473,534	0
Shipping and Handling [Member] | Net Sales [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Shipping and handling fees													83,000	99,000
Shipping and Handling [Member] | Selling Expenses [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Shipping and handling fees													563,000	289,000
Product [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Sales from continuing operations									8,636,126	$ 8,429,132	$ 8,323,845	$ 7,280,723		32,669,826
License														4,010,000
Generators [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Depreciation expense													1,093,000
Subsequent Event [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Operating lease liability															$ 400,000
International [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Sales from continuing operations													15,872,783	16,635,463
Accounts receivable					2,181,000				1,630,000				$ 2,181,000	$ 1,630,000
Intangible assets estimated useful lives													90 days
Minimum [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Intangible assets estimated useful lives													3 years
Maximum [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Intangible assets estimated useful lives													5 years
Restricted Stock [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Dilutive effect of options to purchase shares of common stock | shares				400,000
Shares of restricted common stock | shares													4,000,000	4,000,000
SonaCare Medical ("SonaCare") [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Proceeds from sale of intangible assets			$ 5,800,000										$ 2,542,579
Earn-out percentage			7.00%
Proceeds from sale of intangible assets			$ 3,000,000
Earn-out percentage			5.00%
Proceeds from sale of intangible assets			$ 5,800,000
Annual Royalty			$ 250,000
Solsys Medical, LLC [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Percentage of Ownership before Transaction	36.00%
Solsys Medical, LLC [Member] | Definitive Agreement [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Stock transaction value	$ 97,000,000
Percentage of Ownership before Transaction	55.00%
MMIT [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Sales from continuing operations													$ 0	$ 525,000
Distribution Rights [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Amount of upfront fees and stocking orders		$ 5,000,000
Number of monthly installments | Number		5
Minimum royalty payments in 2019		$ 2,000,000
Minimum royalty payments in 2018		5,000,000
Reimbursement of technology transfer costs		5,000,000
Stock transaction value		$ 960,000
Patents [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Intangible assets estimated useful lives													17 years
Finite lived intangible assets, net					779,100				$ 757,447				$ 779,100	757,447
Amortization expense													141,200	$ 127,000
Customer [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Textual)
Accounts receivable					$ 493,784								$ 493,784

Inventories (Details)

Inventories (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Inventory Disclosure [Abstract]
Raw material	$ 4,830,207	$ 3,540,205
Work-in-process	224,252	180,442
Finished goods	2,743,361	1,743,497
Inventory, gross	7,797,820	5,464,144
Less valuation reserve	(444,258)	(444,258)
Inventory, net	$ 7,353,562	$ 5,019,886

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 14,744,531	$ 13,211,613
Less: accumulated depreciation and amortization	(10,545,810)	(9,023,235)
Property, plant and equipment, net	4,198,721	4,188,378
Demonstration and consignment inventory [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	9,076,970	8,227,878
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,793,908	2,582,244
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,471,371	1,464,325
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	691,751	691,751
Software Systems [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	688,203	223,087
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 22,328	$ 22,328

Property, Plant and Equipment_3

Property, Plant and Equipment (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment (Textual)
Depreciation and amortization	$ 1,500,000	$ 1,300,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($)		Jun. 30, 2019	Jun. 30, 2018
Payables and Accruals [Abstract]
Accrued payroll, payroll taxes and vacation		$ 488,339	$ 351,435
Accrued bonus		622,115	552,988
Accrued commissions		662,007	742,807
Professional fees		181,313	102,065
Deferred foreign vendor taxes	[1]		401,000
Vendor, tax and other accruals		534,740	661,877
Accrued expenses and other current liabilities		$ 2,488,514	$ 2,812,172
[1]	Reclassified to non-current liabilities in fiscal 2019

Stock-Based Compensation Plan_2

Stock-Based Compensation Plans (Details) - shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	255,000	305,500
Exercised	245,835	76,418
Outstanding	1,163,856	1,330,193	517,361
Available For Issuance	561,552
2001 Employee Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	1,000,000
Granted	1,251,261
Exercised	376,368
Expired / Forfeited	869,455
Outstanding	5,438
Available For Issuance
2005 Employee Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	500,000
Granted	547,125
Exercised	494,200
Expired / Forfeited	48,925
Outstanding	4,000
Available For Issuance
2005 Non Employee Director Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	500,000
Granted	195,000
Exercised	127,500
Expired / Forfeited	52,500
Outstanding	15,000
Available For Issuance
2009 Employee Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	500,000
Granted	624,925
Exercised	399,407
Expired / Forfeited	129,350
Outstanding	96,168
Available For Issuance
2009 Non Employee Director Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	200,000
Granted	230,000
Exercised	60,000
Expired / Forfeited	56,250
Outstanding	113,750
Available For Issuance	4,425
2012 Employee Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	500,000
Granted	732,000
Exercised	190,999
Expired / Forfeited	242,501
Outstanding	298,500
Available For Issuance	10,501
2012 Non Employee Director Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	200,000
Granted	237,500
Exercised	37,500
Expired / Forfeited	56,250
Outstanding	143,750
Available For Issuance	18,750
2014 Employee Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	750,000
Granted	945,000
Exercised	81,874
Expired / Forfeited	223,876
Outstanding	639,250
Available For Issuance	28,876
2017 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial Shares	750,000
Granted	285,000
Exercised
Expired / Forfeited	37,000
Outstanding	248,000
Available For Issuance	499,000

Stock-Based Compensation Plan_3

Stock-Based Compensation Plans (Details 1)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Equity [Abstract]
Risk-free interest rates	2.80%	1.98%
Expected option life in years	6 years 2 months 30 days	5 years 11 months 12 days
Expected stock price volatility	56.01%	57.42%
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation Plan_4

Stock-Based Compensation Plans (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Outstanding Shares
Outstanding at beginning	1,330,193	517,361
Vested and exercisable at beginning	681,316	517,361
Granted	255,000	305,500
Exercised	(245,835)	(76,418)
Forfeited	(160,502)	(15,125)
Expired	(15,000)	(75,000)
Outstanding at ending	1,163,856	1,330,193
Vested and exercisable at ending	656,730	681,316
Weighted Average Exercise Price
Outstanding at beginning	$ 8.47	$ 7.66
Vested and exercisable at beginning	7.67	6.33
Granted	16.64	10.10
Exercised	7.96	5.47
Forfeited	10.15	7.89
Expired	2.66	4.87
Outstanding at ending	10.28	8.47
Vested and exercisable at ending	$ 8.42	$ 7.67
Aggregate Intrinsic Value
Outstanding at beginning	$ 5,369,557	$ 2,748,956
Vested and exercisable at beginning	3,355,240	1,923,794
Outstanding at ending	17,617,231	5,369,557
Vested and exercisable at ending	$ 11,162,650	$ 3,355,240

Stock-Based Compensation Plan_5

Stock-Based Compensation Plans (Details 3)	12 Months Ended
	Jun. 30, 2019$ / sharesshares
Options Outstanding, Number, shares | shares	1,163,856
Options Outstanding, Weighted Average Contractual Life (Yrs.)	6 years 10 months 25 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 10.28
Options Exercisable, Number, shares | shares	656,730
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 8.42
Exercise Prices 1.82 - 6.98 [Member]
Options Outstanding, Number, shares | shares	225,106
Options Outstanding, Weighted Average Contractual Life (Yrs.)	4 years 7 months 6 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 4.89
Options Exercisable, Number, shares | shares	183,606
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 4.47
Exercise Prices 6.99 - 9.45 [Member]
Options Outstanding, Number, shares | shares	237,125
Options Outstanding, Weighted Average Contractual Life (Yrs.)	5 years 10 months 25 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 8.21
Options Exercisable, Number, shares | shares	197,249
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 8.14
Exercise Prices 9.46 - 10.23 [Member]
Options Outstanding, Number, shares | shares	246,125
Options Outstanding, Weighted Average Contractual Life (Yrs.)	7 years 10 months 25 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 9.84
Options Exercisable, Number, shares | shares	124,625
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 9.74
Exercise Prices 10.24 - 13.35 [Member]
Options Outstanding, Number, shares | shares	223,500
Options Outstanding, Weighted Average Contractual Life (Yrs.)	6 years 10 months 25 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 11.75
Options Exercisable, Number, shares | shares	149,250
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 12.49
Exercise Prices 13.36 - 19.84 [Member]
Options Outstanding, Number, shares | shares	232,000
Options Outstanding, Weighted Average Contractual Life (Yrs.)	9 years 3 months 19 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 16.7
Options Exercisable, Number, shares | shares	2,000
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 13.89

Stock-Based Compensation Plan_6

Stock-Based Compensation Plans (Details Textual) - USD ($)	Dec. 15, 2016	Jun. 30, 2019	Jun. 30, 2018
Stock-Based Compensation Plans (Textual)
Compensation cost		$ 2,336,139	$ 2,628,828
Unrecognized compensation cost		$ 3,770,549
Period of recognition		2 years 7 months 6 days
Option expiration period		2 years 3 months 19 days
Stock options granted, outstanding		255,000	305,500
Weighted average fair value at date of grant for options		$ 16.64	$ 5.50
Fair value of shares vested		$ 2,351,268
Number of non-vested stock options		648,877
Weighted-average grant-date fair value of non-vested stock options (in dollars per share)		$ 5.08
Number of vested stock options		240,624
Weighted-average grant-date fair value of stock options		$ 5.14
Amount of non-vested options forfeited			$ 625,202
Additional amortization of award		$ 475,286
Restricted Stock [Member]
Stock-Based Compensation Plans (Textual)
Unrecognized compensation cost		1,133,743
Fair value of shares vested		$ 133,333
Description of restricted stock awards		The compensation cost that has been charged against income for these plans, excluding the compensation cost for restricted stock, was $1,221,233 and $1,728,491 for the fiscal years ended June 30, 2019 and 2018, respectively.
Restricted Stock [Member] | Chief Executive Officer [Member]
Stock-Based Compensation Plans (Textual)
Option vesting period	5 years
Fair value of shares vested	$ 3,600,000
Compensation expense		$ 1,114,906	$ 900,337
Number of stock issued	400,000
Description of restricted stock awards		The Company has estimated that it is probable that the performance conditions will be met. The awards were valued using a Monte Carlo valuation model using a stock price at the date of grant of $9.60, a term of 3 to 5 years, a risk free interest rate of 1.6% to 2.1% and a volatility factor of 66.5%.
Stock Options [Member]
Stock-Based Compensation Plans (Textual)
Option expiration period		10 years
Option vesting period		4 years

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 365,942
2021	96,517
Total minimum lease payments	$ 462,459

Commitments and Contingencies_3

Commitments and Contingencies (Details Textual) - USD ($)	Mar. 24, 2017	Jun. 30, 2019	Jun. 30, 2018
Commitments and Contingencies (Textual)
Rent expense		$ 422,000	$ 435,000
Settlement amount	$ 500,000
Investigative costs, description		The investigative costs to date, including costs of litigation relating to the Company’s former Chinese distributor as described below, are approximately $3.9 million to date, of which $0.8 million, $0.5 million and $2.4 million was charged to expense during the three years ended June 30, 2019, respectively.
Attorneys fee		$ 500,000
Expiring date		30-06-2021
Building [Member]
Commitments and Contingencies (Textual)
Rent expense		$ 29,000
Frequency of rent expense		Monthly
Inventories [Member]
Commitments and Contingencies (Textual)
Purchase and inventory commitments		$ 5,518,842	$ 3,841,641
Former Chinese Distributor - FCPA [Member]
Commitments and Contingencies (Textual)
Investigative costs		250,000
Former Chinese Distributor - FCPA [Member] | General and Administrative Expense [Member]
Commitments and Contingencies (Textual)
Investigative costs		$ 50,000

Related Party Transactions (Det

Related Party Transactions (Details) - Applied BioSurgical [Member] - Mr. Stavros G. Vizirgianakis [Member] - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Sales	$ 1,405,430	$ 999,719
Accounts receivable	$ 221,240	$ 239,062

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Deferred tax assets / (liabilities)
Bad debt reserves	$ 22,977	$ 45,817
Inventory reserves	238,430	194,363
Accruals and allowances	195,789	18,938
Net operating loss carryforwards	3,875,978	2,738,775
Tax credits	683,659	496,898
Foreign tax credits	401,000	401,000
Stock based compensation	572,378	516,733
Deferred gain - HIFU and Labcaire	92,138	91,862
Amortization	(371,940)	(378,818)
Depreciation	(124,305)	(36,088)
Long-term Contract	(220,583)
Other	9,651	6,873
Total deferred tax assets liabilities non-current	5,375,172	4,096,353
Valuation Allowance	(5,375,172)	(4,096,353)
Total net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Dec. 22, 2017	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Current:
Federal
State										28,547
Foreign											401,000
Total current										28,547	401,000
Deferred:
Federal	$ 1,755,823										5,116,778
State											(101,132)
Total deferred											5,015,646
Total income tax expense (benefit)		$ 28,547				$ 173,224		$ 5,524,422	$ (281,000)	$ 28,547	$ 5,416,646

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Tax at federal statutory rates									$ (1,541,883)	$ (483,207)
State income taxes, net of federal benefit									22,552	(102,812)
Research credit									(186,761)	(216,099)
Stock-based compensation									35,923	306,678
Valuation allowance									1,194,917	4,096,353
Reduction of deferred tax asset related to Tax Legislation										1,755,823
Meals									25,116	12,458
Transaction Costs									293,256
Long-term Contracts									201,600
Other									(16,173)	47,452
Total income tax expense (benefit)	$ 28,547				$ 173,224		$ 5,524,422	$ (281,000)	$ 28,547	$ 5,416,646

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	Dec. 22, 2017	Jun. 30, 2019	Jun. 30, 2018
Income Taxes (Textual)
Discrete tax expense	$ 1,755,823		$ 5,116,778
Minimum tax credit	$ 169,000
Deferred tax assets, valuation allowance		5,375,172
Domestic operating loss carryforwards		17,178,000
U.S. federal net operating loss carryforwards		10,504,000
Unexpired carryforwards amount		6,674,000
Tax benefits related to exercised stock options		2,491,000
Research and development tax credits carryforwards		$ 684,000
U.S. deferred tax assets at lower	21.00%
Description of statutory tax rate		The Tax Legislation reduces the U.S. statutory tax rate from 35% to 21%, effective January 1, 2018. U.S. tax law requires that taxpayers with a fiscal year that begins before and ends after the effective date of a rate change calculate a blended tax rate based on the pro rata number of days in the fiscal year before and after the effective date. As a result, for the fiscal year ended June 30, 2018, the Company’s U.S. statutory income tax rate was 27.55%.
Net operating loss carryforwards, description		The Company had approximately $17,178,000 of U.S. federal net operating loss carryforwards of which $10,504,000 will expire in tax years between 2031 and 2037 and $6,674,000 will not expire. Included in U.S. Federal net operating loss carryforward amount are windfall tax benefits related to exercised stock options of approximately $2,491,000, the benefit of which was recorded in equity when the Company adopted ASU 2016-09 beginning in fiscal 2018. The Company has approximately $684,000 of research and development tax credit carryforwards which expire in the tax years between 2026 and 2038.
Deferred tax assets [Member]
Income Taxes (Textual)
Deferred tax assets, valuation allowance		$ 1,278,819

Employee Profit Sharing Plan (D

Employee Profit Sharing Plan (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Employee Profit Sharing Plan (Textual)
Exceed age limit of employee	50 years
Amount of maximum annual contributions by employee	$ 24,000
Percentage of employer contribution	10.00%
Contribution amount	$ 55,297	$ 58,162

Segment Reporting (Details)

Segment Reporting (Details) - USD ($)	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Total	$ 9,754,284	$ 9,556,590	$ 10,176,453	$ 9,361,164	$ 8,636,126	$ 12,439,132	$ 8,323,845	$ 7,280,723	$ 38,848,491	$ 36,679,826
Consumables [Member]
Total									28,371,517	23,596,476
Equipment [Member]
Total									10,476,974	9,073,350
License [Member]
Total										4,010,000
Domestic [Member]
Total									22,975,708	20,044,363
Domestic [Member] | Consumables [Member]
Total									20,561,273	17,735,749
Domestic [Member] | Equipment [Member]
Total									2,414,435	2,308,614
Domestic [Member] | License [Member]
Total
International [Member]
Total									15,872,783	16,635,463
International [Member] | Consumables [Member]
Total									7,810,244	5,860,727
International [Member] | Equipment [Member]
Total									8,062,539	6,764,736
International [Member] | License [Member]
Total										$ 4,010,000

Segment Reporting (Details Text

Segment Reporting (Details Textual)	12 Months Ended
	Jun. 30, 2019Segment
Segment Reporting [Abstract]
Number of operating segment	1

Quarterly Results (Unaudited)_2

Quarterly Results (Unaudited) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Total revenue	$ 9,754,284	$ 9,556,590	$ 10,176,453	$ 9,361,164	$ 8,636,126	$ 12,439,132	$ 8,323,845	$ 7,280,723	$ 38,848,491	$ 36,679,826
Cost of goods sold	2,968,146	2,801,571	3,048,079	2,750,543	2,519,824	2,631,893	2,465,826	2,177,355	11,568,339	9,794,898
Gross profit	6,786,138	6,755,019	7,128,374	6,610,621	6,116,302	9,807,239	5,858,019	5,103,368	27,280,152	26,884,928
Operating expenses:
Selling expenses	4,393,479	4,414,710	4,800,643	4,735,005	4,430,732	4,447,421	3,919,515	3,570,713	18,343,837	16,368,381
General and administrative expenses	3,835,131	2,512,510	2,347,184	3,183,384	2,184,062	1,925,086	2,380,860	2,573,131	11,878,209	9,063,139
Research and development expenses	897,501	1,426,483	839,219	1,304,766	1,335,776	1,199,895	957,204	901,274	4,467,969	4,394,149
Total operating expenses	9,126,111	8,353,703	7,987,046	9,223,155	7,950,570	7,572,402	7,257,579	7,045,118	34,690,015	29,825,669
Loss from operations	(2,339,973)	(1,598,684)	(858,672)	(2,612,534)	(1,834,268)	2,234,837	(1,399,560)	(1,941,750)	(7,409,863)	(2,940,741)
Other income/(expense):
Interest income	30,148	22,653	17,242	19,813	16,991	9,074	45	13	89,856	26,123
Royalty income and license fees					1	916	71,550	452,971		525,438
Other	(7,425)	(13,650)	1,097	(18,265)	16,831	(5,712)	(4,387)	(4,458)	(38,243)	2,274
Total other income	22,723	9,003	18,339	1,548	33,823	4,278	67,208	448,526	51,613	553,835
(Loss) from continuing operations before income taxes	(2,317,250)	(1,589,681)	(840,333)	(2,610,986)	(1,800,445)	2,239,115	(1,332,352)	(1,493,224)	(7,358,250)	(2,386,906)
Income tax (benefit)	28,547				173,224		5,524,422	(281,000)	28,547	5,416,646
Net (loss) from continuing operations	(2,345,797)	(1,589,681)	(840,333)	(2,610,986)	(1,973,669)	2,239,115	(6,856,774)	(1,212,224)	(7,386,797)	(7,803,552)
Discontinued operations:
Net income (loss) from discontinued operations, net of tax					191,117					191,117
Net income from discontinued operations										(191,117)
Net (loss)	$ (2,345,797)	$ (1,589,681)	$ (840,333)	$ (2,610,986)	$ (1,782,552)	$ 2,239,115	$ (6,856,774)	$ (1,212,224)	$ (7,386,797)	$ (7,612,435)
Net (loss) per share from continuing operations - Basic (in dollars per share)					$ (0.22)	$ 0.24	$ (0.76)		$ (0.79)	$ (0.87)
Net income per share from discontinued operations - Basic (in dollars per share)					0.02					0.02
Net (loss) per share - Basic (in dollars per share)	$ (0.25)	$ (0.17)	$ (0.09)	$ (0.29)	(0.20)	0.24	(0.76)	$ (0.14)	(0.79)	(0.85)
Net (loss) per share from continuing operations - Diluted (in dollars per share)					(0.22)	0.23	(0.76)	(0.14)	(0.79)	(0.87)
Net income per share from discontinued operations - Diluted (in dollars per share)					0.02					0.02
Net (loss) per share - Diluted (in dollars per share)	$ (0.25)	$ (0.17)	$ (0.09)	$ (0.29)	$ (0.20)	$ 0.23	$ (0.76)	$ (0.14)	$ (0.79)	$ (0.85)
Weighted average shares - Basic (in shares)	9,428,938	9,390,665	9,322,237	9,100,123	9,037,046	9,028,506	8,977,984	8,958,405	9,333,117	9,009,189
Weighted average shares - Diluted (in shares)	9,428,938	9,390,665	9,322,237	9,100,123	9,037,046	9,549,144	8,977,984	8,958,405	9,333,117	9,009,189
Product [Member]
Total revenue					$ 8,636,126	$ 8,429,132	$ 8,323,845	$ 7,280,723		$ 32,669,826
License [Member]
Total revenue						$ 4,010,000				$ 4,010,000

Schedule II (Details)

Schedule II (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Allowance for doubtful accounts [Member]
Description
Balance at beginning of period	$ 200,000	$ 96,868
Additions charged (credited) to cost and expenses		103,132
(Deductions)	(100,000)
Balance at end of period	100,000	200,000
Deferred tax valuation allowance [Member]
Description
Balance at beginning of period	4,096,353	628,730
Additions charged (credited) to cost and expenses	1,278,819	3,467,623
(Deductions)
Balance at end of period	$ 5,375,172	$ 4,096,353